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ABSTRACT
THE QUANTITATIVE ASSESSMENT OF OSTEOINDUCTIVITY OF 
HUMAN DEMINERALIZED BONE MATRIX AND cDNA ARRAY ANALYSIS OF
OSTEOGENIC DIFFERENTIATION IN HUMAN PERIOSTEAL CELLS
Sittisak Honsawek 
Old Dominion University and Eastern Virginia Medical School, 2003 
Director: Dr. Lloyd Wolfinbarger, Jr.
Demineralized bone matrix (DBM) has been extensively utilized in orthopeadic, 
periodontal, and maxillofacial applications. DBM comprises bone morphogenetic 
proteins (BMPs) that are essential regulators for endochondral bone formation. The 
current study was undertaken to establish the quantitative in vitro assays for determining 
the osteoinductive potential of human DBM and the use of cDNA gene expression array 
technology for examining gene expression profiles during osteoblast differentiation in 
human periosteal cells.
BMP-4 is one of the most osteoinductive factors and has been investigated for 
clinical applications. For this reason, BMP-4 was designated as the osteoinductive 
protein for use in the quantitative in vitro assay. At the same time, the osteoinductivity of 
DBM was measured by histomorphometric analysis of new bone formation in an in vivo 
athymic mouse bioassay. DBM exhibiting high osteoinductivity in the nude mouse 
bioassay contained higher amounts of extractable BMP-4 than did DBM samples 
possessing low osteoinductivity.
In the study of the effect of residual calcium on extractability of BMP-4, the 
extractable BMP-4 content was undetectable in nondemineralized bone matrix. As the 
residual calcium level decreased, the extractability ofBMP-4 in DBM increased. DBM
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particles less than 250 microns yielded the lowest amounts of extractable BMP-4 among 
all size groups tested. Bone particles in the 500-710 micron size range provided for 
DBM with the highest extractability of BMP-4. In the donor age study, the BMP-4 
content in the protein extracts of DBM appears to be age-dependent, with DBM from 
younger donors being most likely to have greater BMP-4 quantity.
In the in vitro dose-response studies, DBM-conditioned media (DBM-CM) 
enhanced alkaline phosphatase activities of human periosteal cells in a dose-dependent 
fashion. Alkaline phosphatase activities in both biochemical and histochemical analysis 
increased in the DBM-CM treated flasks compared to non-treated flasks after five days of 
incubation. In gene expression analysis of osteogenic differentiation using cDNA array 
analysis, a few differentially expressed genes, including biglycan, TGF-pi, and TGF-|3R1 
were up-regulated, whereas collagenl4Al was down-regulated in response to DBM-CM 
treatment. In the present study, gene expression array technology provides insight to the 
biological process of osteogenic differentiation.
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Bone consists of cells and extracellular matrix. The extracellular bone matrix is 
comprised of 35% organic and 65% inorganic components. The inorganic components 
are mainly calcium and phosphate as hydroxyapatite. The organic components of bone 
matrix are divided into collagen and noncollagenous proteins. Type I collagen 
constitutes more than 90% of the organic material in bone matrix and is the major 
structural protein of bone. The remaining 10%, the non-collagenous proteins, have 
different regulatory functions for mineralization, mediation of cell-to-matrix binding, and 
various interactions with structural proteins, such as collagen. Cells responsible for the 
production of the bone matrix constituents collagen and ground substance are bone- 
forming cells or osteoblasts. The mature osteoblasts are post-proliferative, cuboidal, 
strongly alkaline phosphatase positive cells lining bone matrix at sites of active matrix 
production. The mature osteoblast phenotype is characterized by the ability of the cells 
to synthesize membrane-associated alkaline phosphatase, bone matrix molecules 
including type I collagen, and a variety of non-collagenous proteins, such as osteocalcin, 
and bone sialoprotein.
1.1 Bone cells
Four primary cell types are responsible for the formation and resorption of mature 
bone: (1) osteoblasts, (2) osteocytes, (3) lining cells, and (4) osteoclasts.
The journal model is Journal o f Dental Research.
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1.1.1 Osteoblasts
The fully differentiated osteoblasts produce and secrete proteins that constitute the 
bone matrix (Robey et a l, 1995). The matrix is subsequently mineralized under the 
control of the same cells. A major product of the bone-forming osteoblast is type I 
collagen. This polymeric protein is initially secreted in the form of a precursor, which 
contains peptide extensions at both the amino-terminal and carboxyl ends of the 
molecule. The propeptides are proteolytically cleaved. Further extracellular processing 
results in mature three-chained type I collagen molecules, which then assemble 
themselves into a collagen fibril. Individual collagen molecules become interconnected 
by the formation of pyridinoline cross-links, which are unique to bone. Bone-forming 
osteoblasts synthesize a number of other proteins that are incorporated into the bone 
matrix, including osteocalcin and osteonectin, which constitute 40% to 50% of the 
noncollagenous proteins of bone. Mice deficient in osteocalcin develop a phenotype 
marked by higher bone mass and improved bone quality suggesting that osteocalcin 
functions normally to limit bone formation without compromising mineralization (Ducy 
et al, 1996). Conversely, mice deficient in osteonectin exhibit decreased osteoclast and 
osteoblast numbers and bone remodeling and profound osteopenia suggesting that under 
normal conditions, this protein may play a role in the birth or survival of these cells 
(Delany et a l, 1998). Other osteoblast-derived proteins include glycosaminoglycans, 
which are attached to one of two small core proteins: biglycan and decorin. The latter 
protein has been implicated in the regulation of collagen fibrillogenesis. A number of 
other minor proteins such as osteopontin, bone sialoprotein, fibronectin, vitronectin, and 
thrombospondin serve as attachment factors that interact with integrins.
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In addition to being the cells that produce the osteoid matrix, mature osteoblasts 
are essential for its mineralization, the process of deposition of hydroxyapatite (Boskey, 
1998; 1996). Osteoblasts are thought to regulate the local concentrations of calcium and 
phosphate in such a way as to promote the formation of hydroxyapatite. Osteoblasts 
express relatively high amounts of alkaline phosphatase, which is anchored to the 
external surface of the plasma membrane. Alkaline phosphatase has been thought to play 
a role in bone mineralization. Consistent with this, deficiency of alkaline phosphatase 
due to genetic defects leads to hypophosphatasia, a condition characterized by defective 
bone mineralization (Whyte, 1994). However, the precise mechanism of mineralization 
and the exact role of alkaline phosphatase in this process remain unclear. Matrix 
synthesis determines the volume of bone but not its density. Mineralization of the matrix 
increases the density of bone by displacing water, but does not alter its volume.
1.1.2 Osteocytes
Some osteoblasts are eventually buried within lacunae of mineralized matrix. 
These cells are termed osteocytes and are characterized by a striking stellate morphology, 
reminiscent of the dendritic network of the nervous system (Marotti et a l, 1990;
Nijweide et al., 1996). Osteocytes are the most abundant cell type in bone. Osteocytes 
are 10 times more than osteoblasts. Osteocytes are regularly spaced throughout the 
mineralized matrix and communicate with each other and with cells on the bone surface 
via multiple extensions of their plasma membrane that run along the canaliculi. 
Osteoblasts, in turn, communicate with cells of the bone marrow stroma which extend 
cellular projections onto endothelial cells inside the sinusoids. Thus, a syncytium extends 
from the embedded osteocytes all the way to the vessel wall (Marotti, 1996). Osteocytes
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sense changes in interstitial fluid flow through canaliculi and detect changes in the levels 
of hormones, such as estrogen and glucocorticoids, that influence their survival and that 
circulate in the same fluid (Weinstein et al., 1998; Tomkinson et al.  ̂ 1998; 1997). 
Therefore, disruption of the osteocyte network is likely to increase bone fragility.
1.1.3 Lining cells
The surface of normal quiescent bone is covered by a 1-2 pm thick layer of 
unmineralized collagen matrix on top of which there is a layer of flat and elongated cells. 
These cells are called lining cells and are descendents of osteoblasts (Parfitt, 1994). 
Conversion of osteoblasts to lining cells represents one of the fates of osteoblasts that 
have completed their bone forming function. Osteoclasts cannot attach to the 
unmineralized collagenous layer that covers the surface of normal bone. Therefore, the 
lining cells secrete collagenase, which removes this matrix before osteoclasts can attach 
to bone. Targeting of osteoclast precursors to a specific location on bone depends on a 
homing signal given by lining cells. The lining cells are signaled by osteocytes. 
Osteocytes are the only bone cells that can sense the need for remodeling at a specific 
time and place (Parfitt etal., 1996).
1.1.4 Osteoclasts
Mature osteoclasts are usually large multinucleated cells with abundant 
mitochondria, numerous lysosomes, and free ribosomes. Their most remarkable 
morphological feature is the ruffled border, a complex system of finger-shaped 
projections of the membrane. Its function is to mediate the resorption of the calcified 
bone matrix (Roodman, 1996; Boskey, 1998). This structure is completely surrounded 
by another specialized area, called the clear zone. The cytoplasm in the clear zone area
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has a uniform appearance and contains bundles of actin-like filaments. The clear zone 
delineates the area of attachment of the osteoclast to the bone surface and seals off a 
distinct area of the bone surface that lies immediately underneath the osteoclast and 
which eventually will be excavated. The ability of the clear zone to seal off this area of 
bone surface allows the formation of a microenvironment suitable for the operation of the 
resorptive apparatus.
The mineral component of the matrix is dissolved in the acidic environment of the 
resorption site, which is created by the action of an ATP-driven proton pump located in 
the ruffled border membrane. The protein components of the matrix, mainly collagen, 
are degraded by matrix metalloproteinases, and cathepsins K, B, and L are secreted by 
the osteoclast into the area of bone resorption (Bossard et al., 1996). The degraded bone 
matrix components are endocytosed along the ruffled border within the resorption 
lacunae and then transcytosed to the membrane area opposite the bone, where they are 
released (Nesbitt etal., 1997; Salo et al., 1997). Another feature of osteoclasts is the 
presence of high amounts of the phosphohydrolase enzyme, tartrate-resistant acid 
phosphatase (TRAPase). This feature is commonly used for the detection of osteoclasts 
in bone specimens (Udagawa et al, 1990). Mice deficient in TRAPase exhibit a mild 
osteopetrotic phenotype due to an intrinsic defect of osteoclastic resorptive activity and 
defective mineralization of the cartilage in developing bones (Hayman et al., 1996).
1.2 Bone matrix
The mineral phase of bone is nucleated, propagated, and remodeled within the 
scaffolding provided by the extracellular matrix. This organic scaffolding consists 
primarily of large protein components that have the capacity to form macromolecular
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aggregates, the organization of which establishes the bone superstructure. Also 
incorporated into the scaffolding superstructure are relatively small proteins that appear 
to act in the communication between the matrix and the cells in bone (Gehron et al.,
1996). The matrix components of bone consist of three classes of macromolecule. The 
first group possesses repetitive structural motifs (collagen, hyaluronan, decorin, and 
biglycan), while the second group possesses a modular domain structure (versican, 
thrombospondin, fibronectin, osteonectin, and tenascin). In contrast, the structural motifs 
that convey functionality of the third group (MGP, osteopontin, BSP, and osteocalcin) are 
not as well defined.
1.2.1 Bone matrix proteins with repetitive structure
The major organic component of the bone extracellular matrix is type I collagen, 
accounting for up to 90% of the organic matrix. This interstitial, fibril-forming substance 
is composed of trimers of two a 1(1) chains and one a2(I) chain. The repetitive motif Gly- 
X-Y, where X and Y are often proline and its hydroxylated derivative, enables the 
formation of stable triple helices. The molecular form of collagen secreted into the 
extracellular matrix is procollagen, where the three a  chains possess amino and carboxyl- 
terminal polypeptide extensions. Collagen fibril formation occurs following cellular 
secretion and enzymatic removal of the noncollagenous N- and C-terminal extensions. 
Procollagen processing is influenced by posttranslational modifications (hydroxylation of 
lysyl and prolyl residues and glycosylation) and the binding of other matrix components 
such as proteoglycans (Brown et al, 1989; Fessler et al, 1978; Vogel et al, 1984). 
Mutations in type I collagen are also associated in vitro with alterations in the levels of 
other bone matrix components, with some components being reduced (osteonectin,
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versican, decorin, and biglycan) and others elevated (hyaluronan, fibronectin, and 
thrombospondin) in the matrix (Fedarko etal., 1992; 1995). Normal collagen 
metabolism appears to play a role not only in structural integrity but also in cellular 
feedback and bone cell proliferation/differentiation (Celic etal., 1998; Fedarko etal, 
1996; Shi etal., 1996).
Hyaluronan or hyaluronic acid is found in bone (Oohira et al, 1989), is 
synthesized by bone cells in culture, and has been proposed to capture space for 
subsequent matrix deposition (Fedarko et al, 1990; Fisher et al., 1985). Hyaluronan is a 
component of immature bone matrix, and its increased levels in 01 bone matrix are 
consistent with the early, immature bone matrix, being less structurally rigid than the 
mature, highly collagenous matrices. CD44, which is thought to be a cell surface 
receptor for hyaluronan (Culty et a l, 1994), has been colocalized with hyaluronan on 
osteoclasts, osteoblasts, and osteocytes (Noonan et a l, 1996).
Proteoglycans comprise a family of molecules that possess a core protein to which 
one or more glycosaminoglycan chains are covalently attached. Decorin and biglycan are 
interstitial proteoglycans found in many connective tissues, including bone (Fisher, 1985; 
Almond et al., 1998). Decorin binds to the collagen fibrils (Weber et a l, 1996), while 
biglycan is found in pericellular areas, including that of osteoblasts and osteocytes 
(Fleischmajer et a l, 1991). The small proteoglycans may act as matrix organizers, 
orienting and ordering the collagen fibrils with the protein portion binding to collagen 
fibrils at specific sites and the glycosaminoglycan chains aggregating to hold the proteins, 
and the collagen fibrils, at defined distances from each other (Bianco et al., 1990).
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Studies involving in vitro assays have shown that decorin inhibits the growth of collagen 
fibrils (Brown etal., 1989; Vogel etal., 1984).
1.2.2 Modular domain proteins
Human bone cells produce a large chondroitin sulfate proteoglycan that is 
versican-like (Fedarko et al., 1990). Although the exact function of bone versican is not 
known, it has been proposed to act as a space filler in fetal and very young bone, to be 
replaced by osteoid during later development (Fisher, 1985). This versican-like 
proteoglycan can bind hyaluronan (Fedarko et al., 1990). Its biosynthetic level is 
elevated in fetal and neonatal osteoblast-like cells and decreases with increasing donor 
age (Fedarko et al., 1992).
Thrombospondins and fibronectin exemplify proteins found in bone that are 
composed of various combinations and amounts of modular structures. In addition, they 
contain the arginine-glycine-aspartate (RGD) cell attachment consensus sequence and are 
believed to play a role in cell-matrix adhesion via binding to integrin receptors on the 
cells surface (Gehron et al., 1987). Thrombospondin is synthesized by osteoblastic cells 
(Asch et al., 1989). The various isoforms are expressed at different anatomical sites at 
different times in bone (Gehron et al., 1989; Grzesik et a l, 1994; Tooney et al., 1998). 
Fibronectin has the capacity to modulate cell migration, cell attachment, and matrix 
organization. It contains binding domains for fibrin/heparin, gelatin/collagen, and cell 
surfaces. Fibronectin is synthesized by and maintained around osteoblasts during 
osteogenesis (Mould etal., 1990). In early bone formation, osteoblasts depend on 
fibronectin for differentiation signals, while at later stages, the cells depend on
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fibronectin for survival, becoming apoptotic when antifibronectin antibodies are used to 
block cellular interactions (Weiss etal., 1981).
Osteonectin (also termed secreted protein, acidic and rich in cysteine (SPARC)) is 
a Ca2+-binding glycoprotein found in many connective tissues, though relatively high 
concentrations are present in bone (Globus etal., 1998). Osteonectin binds to calcium, 
hydroxyapatite, and collagen and, therefore, was originally hypothesized to be involved 
in mineralization of bone (Globus et al., 1998). Osteonectin expression levels may be 
related to rapid cell proliferation, matrix remodeling, and epithelial-mesenchymal 
interactions (Raines etal., 1992; Holland etal., 1987; Tremble etal., 1993).
Tenascin (also known as hexabrachion and cytotactin) comprises an extracellular 
matrix family of glycoproteins and is involved in developmental processes such as 
morphogenetic cell migration and organogenesis. Tenascin is present in developing 
cartilage and bone, localizing to the condensing mesenchyme of osteogenic cells invading 
the cartilage (Seiffert et al., 1998). It is not detectable in mature bone matrix but is 
present on periosteal and endosteal surfaces. Tenascin inhibits chondrocyte attachment to 
fibronectin and by modulating fibronectin-cell interactions may affect cell rounding and 
condensation (Seiffert et al, 1998).
1.2.3 Structureless matrix proteins
The RGD-containing sialoproteins osteopontin and bone sialoprotein (BSP) are 
produced by osteogenic cells that are reaching maturity, and their deposition leads to the 
first detectable mineralized matrix (Kessler et al., 1996). Osteopontin has an acidic 
amino terminus with a polyaspartic acid sequence. Similar to BSP, osteopontin has 
sequences for serine phosphorylation, N-linked oligosaccharide attachment, and tyrosine
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sulfation. The RGD is located in the carboxy-terminal region and is flanked by a 
thrombin cleavage site. Immunolocolization of osteopontin revealed the highest density 
of gold particles associated with electron-dense organic material (Weber et al., 1997). 
Osteopontin is a potent inhibitor of hydroxyapatite formation (Chen et al, 1994).
BSP (along with osteocalcin) is considered a defining noncollagenous protein 
marker of the mature osteoblast phenotype. BSP is expressed at late stages of 
osteoblastic differentiation and has been localized to the sites of earliest mineral 
deposition (Flores etal., 1992; Bianco et al, 1991; 1993). Osteocalcin comprises 10% to 
20% of the noncollagenous proteins in bone, depending on developmental age and the 
species. Levels of osteocalcin are low at early stages of bone formation and increase with 
increasing age. The function of osteocalcin may be to inhibit mineralization since 
osteocalcin blocks hydroxyapatite crytal growth in solution (Luo et al, 1995). It has also 
been suggested that osteocalcin may function in bone resorption rather than formation 
(Price et al, 1982). Target disruption of the osteocalcin gene in mice yielded a 
phenotype of increased bone mass and strength suggesting that this small protein 
normally inhibits bone growth and promotes bone resorption (Lian et a l, 1986).
1.3 Bone formation and bone healing
There are three basic principles responsible for enhancement of bone healing and 
bone formation: (1) osteoinduction, (2) osteoconduction, and (3) osteogenesis.
1.3.1 Osteoinduction
In addition to the differentiated bone cells (osteoblasts, osteoclasts, and 
osteocytes), bone and adjacent tissues contain a number of undifferentiated cells. These 
undifferentiated cells are important for proper bone healing or anchorage of an implant,
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since they can be recruited to form osteoprogenitor cells and develop into differentiated 
bone cells (Young, 1963). Osteoinduction is the process by which immature cells are 
recruited and stimulated to develop into the bone-forming cell lineage. The classical 
research describing bone induction dates back to Urist’s study in the 1965 (Urist, 1965). 
Demineralized bone was used as an osteoinductive agent. Later, a soluble glycoprotein 
was isolated as the osteoinductive agent called BMP (Urist e ta l, 1979). BMPs are 
naturally released in response to trauma and are the only known inductive agents (Lind, 
1996).
1.3.2 Osteoconduction
Osteoconduction is a process that supports the ingrowth of capillaries, 
perivascular tissues, and osteoprogenitor cells from the recipient host bed into the bone 
conductive material or implanted graft. Normal osteoblastic or osteoblast-like cells have 
the ability to form bone on an appropriate surface. Bone growth on an implant surface 
depends on the action of differentiated bone cells. These cells may originate either in 
pre-existing preosteoblasts or osteoblasts that are activated by trauma or in cells recruited 
from primitive mesenchymal cells by osteoinduction (Frost, 1989). The use of allogenic 
bone grafts and other processed bone graft materials serves mainly as bone conductive 
material.
1.3.3 Osteogenesis
Osteogenesis is the synthesis of new bone by surviving preosteoblasts and 
osteoblasts within a bone autograft. The use of naturally-occuring materials, such as 
autogenous or allogenic bone grafts or autogenous bone marrow grafts, to induce bone 
formation and enhance fracture healing is considered to be osteogenic method. Ceramics,
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like calcium phosphate ceramics and glass ceramics, have osteoconductive properties, but 
are hypothesized to stimulate osteogenesis by releasing non-organic mineral-ions, which 
activates cellular processes during bone formation and healing (Teti ei al,, 1991). Bone 
matrix is a source for growth factors that participate in activation and maintenance of 
cellular processes during bone formation and healing. Some of these growth factors have 
been shown to be able to accelerate bone formation and bone healing when applied 
locally to both intact and healing bone tissue.
2. BONE MORPHOGENETIC PROTEINS
2.1 Biochemistry of bone morphogenetic proteins
BMPs are extractable from bone matrix with chaotropic agents such as 4 M 
guanidine hydrochloride, 8 M urea, or 1% sodium dodecyl sulfate. Proteins with 
comparable bioactivity refer either to recombinant or to partially or highly purified 
proteins. The quantity of human BMPs in bone matrix is small, less than 1 pg/kg. It is 
difficult to purify human BMPs to homogeneity because it forms insoluble aggregates 
with itself and with other noncollagenous proteins in aqueous media. The isolation of 
BMPs from cortical bone involves disassembling the densely packed structure of cortical 
bone matrix. BMPs are so much less abundant in cancellous than in cortical bone that 
only the diaphysis is used for chemical extraction of the BMPs (Urist, 1989).
All of the BMPs are members of the TGF-p superfamily of genes (Wozney, 1998; 
Reddi, 1998; Sakou, 1998). This superfamily currently includes approximately 45 genes. 
Members have been identified in most species including human and mouse, as well as 
Drosophila, Xenopus, zebrafish and Caenorhabditis elegans. The structure of the 
proteins of this superfamily is shown in Figure 1. Each of the proteins is produced as a
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N-terminal signal sequence, a prodomain and a mature domain at the carboxyl terminus. 
The structural hallmark of this superfamily is a highly conserved 7 cysteine motif in the 
mature domain. This domain also contains a relatively short amino terminal extension 
that exhibits considerably more evolutionary divergence. The BMP family is the largest 
subgroup in the TGF-p superfamily of molecules. The original characteristic of this 
family was the ability of its members to induce new bone formation. However, not all 
members in this family have demonstrated this activity.
Protein sequence characterization was the primary goal in the early discovery 
research. Since only microgram amounts were available, success was achieved with 
much difficulty. Multiple proteases were used to cleave the osteoinductive preparations 
and micromethods were necessary for isolation of the peptides. Oligonucleotide probes 
based on peptide sequences from these preparations were constructed and used to screen 
human cDNA libraries. Several genes were identified, including one that was named OP- 
1 and another that had been named BMP-2. Using these data as well as published data on 
other BMPs, the 18-kDa subunit of the bovine osteoinductive preparation was identified 
as the bovine equivalent of mature human OP-1, whereas the 16-kDa subunit was the 
bovine equivalent of mature BMP-2.
Alignment of protein sequences in the cysteine domains reveals striking sequence 
similarities and differences among the superfamily members. Table 1 demonstrates the 
alignment calculated as percent of identical amino acid residues and compares OP- 
l/BMP-7 to the other members (Griffith et al., 1996). The comparison demonstrates the 
different family groupings, including, the BMP, the activin (inhibin) and the TGF-p 
families. When compared to other BMPs, OP-l/BMP-7 is most closely related by
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Figure 1. Schematic of TGF-P superfamily protein structure.
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Table 1. Comparison of representative TGF-P superfamily members: percent identity in 
7 cysteine region
Family member Percent Family member Percent
OP-l/BMP-7 100 GDF-1 45
BMP-5 88 SCREW 47
BMP-6 87 BMP-3B 42
BMP-8 74 BMP-3 42
BMP-8B 67 NODAL 41
60A 69 InhibinpA 43
UNIVTN 63 InliibinfB 38
BMP-2 60 InhibinpC 39
BMP-4 58 TGF-P4 38
dpp 58 TGF-P5 37
Vg-1 57 TGF-P 1 35
GDF-6 53 TGF-p3 37
GDF-7 53 TGF-p2 36
GDF-5 51 BMP-11 36
BMP-9 51 GDF-9 30
DORS ALIN 49 MIS 26
BMP-10 47 GDNF 22
GDF-3 49
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sequence to BMP-5 and BMP-6 with 88% and 87% amino acid sequence identity, 
respectively, in the cysteine rich C-terminus. OP-1 is more distantly related to BMP-2 
and BMP-4, having 60 and 58% identity, respectively. GDF-5, another BMP that has 
been extensively evaluated, has even less similarity, showing 51% identity. BMP-3 is not 
osteoinductive and, in fact, is more distant having 42% identity. The TGF-(3s themselves 
are quite distant from most BMPs and do not exhibit bone inductive activity. Many of 
the newer proteins in the list have not yet been expressed as recombinant proteins and 
thus it is not known if they possess osteoinductive activity. Species comparisons show a 
strong evolutionary conservation. For example, there is a 98% identity in amino acid 
sequences in OP-1 between the human and mouse genes in the conserved mature domain.
The members of the TGF-p superfamily are signaling molecules that are 
responsible for specific morphogenetic events involved in tissue and organ development. 
A number of the members of this superfamily have been identified based on tissue- 
specific functional assays and molecular cloning approaches in various developmental 
systems. The decapentaplegic gene, DPP, and the 60-A gene are responsible for proper 
development of Drosophila melanogaster embryos. In Xenopus laevis, vegetal pole- 
derived transcripts, Vgr-1, and activins have been demonstrated to play a critical role in 
mesoderm induction. In addition, other members of the TGF-P superfamily include: 
Mullerian inhibiting substance (MIS), which causes regression of the Mullerian duct in 
the development of the male reproductive tract; inhibins and activins, which act together 
to regulate the release of follicle-stimulating hormone in the pituitary gland; and growth 
and differentiation factors (GDFs), which are thought to be involved in many aspects of 
tissue morphogenesis.
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Expression of recombinant forms of the early BMPs was accomplished using 
mammalian cell lines, most particularly CHO cells (Sampath et a l, 1992; Wang et al. 
1990). With this expression system, the BMPs are produced and properly refolded inside 
the cells and then secreted into the media in an active form. The BMPs are then purified 
from the media and characterized. Preparations of both OP-1 and BMP-2 used in clinical 
testing and currently in various stages of the regulatory approval process were produced 
by this methodology. However, more recently several BMPs have been produced in 
bacterial cells. Recombinant preparations of GDF-5, 6, and 7 have been produced in 
active form from Escherichia coli (Erlacher et al., 1998; Spiro et a l, 2000). With this 
expression system, the BMPs are produced in a randomly folded state inside the cells and 
after lysing the cells, the BMPs are purified and refolded into the proper conformation. 
BMP-2 has also been successfully produced in E. coli (Scheufler et al., 1999). On the 
other hand, OP-1 has been extensively evaluated in E. coli expression systems but 
appears to be a more formidable refolding challenge and only small amounts of active 
protein have been produced. Other expression systems such as yeast, plants and 
transgenic animals have not been reported for expression of BMPs.
2.2 Structure of bone morphogenetic proteins
As first described for TGF-P, members of the BMP family of proteins are 
synthesized as large precursors that are approximately three times larger than the mature 
protein and are eventually proteolytically processed to yield mature disulfide-linked 
dimers (Jones e ta l, 1994). The expression and processing has been extensively 
examined for OP-l/BMP-7. The OP-1 gene predicts a polypeptide of 431 amino acids 
with a 29 amino acid signal sequence. Residues 293 through 431 comprise the mature
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domain and residues 29 through 292 comprise the prodomain. OP-1 is initially 
synthesized in the cell as a monomeric 50 kDa pro-protein that is dimerized, 
glycosylated, and then proteolytically cleaved at the Arg-Xaa-Xaa-Arg maturation site in 
an acidic cellular compartment before secretion into the medium. Of the four potential 
N-linked glycosylation sites two are used, one in the mature domain and one in the pro­
domain. Secreted OP-1 demonstrates an apparent molecular weight of 110-120 kDa, 
indicating that after proteolytic processing the two pro-domains remain non-covalently 
associated with the disulfide linked mature. During the purification procedure for mature 
OP-1/BMP-7, the prodomain is normally separated from the complex by the use of 
dissociating conditions. However, the intact complex can be purified in the absence of 
these agents and has been characterized. This purified complex is termed soluble or 
proOP-1 and is significantly more soluble in physiological buffers than the mature OP-1. 
The function of the prodomain has not been elucidated. However, in addition to its 
presumed role in protein folding and transport, the prodomain may participate in tissue 
targeting or receptor specificity.
The crystal structure has been reported for the mature dimers of OP-l/BMP-7 and 
BMP-2. The structure to 2.8 A° resolution has shown that OP-l/BMP-7 is in a “hand” 
structure consisting of two fingers of antiparallel beta strands and an alpha helical region 
at the heel of the palm (Griffith et a l, 1996). The central core of the hand or palm is the 
site of a threaded ring structure created by the internal disulfide bonds also known as the 
cysteine knot. An intermolecular disulfide bond in this “palm” region forms the dimer. 
Envisioning a handshake provides a conceptual picture of this dimer interaction. The 
three-dimensional structure to 2.7 A0 has recently been published for the BMP-2
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molecule and shown to be very similar to that of OP-1 (Scheufler et a l, 1999). Most 
recently, the crystal structure of a BMP-2: BMPR-1A receptor ectodomain complex was 
solved (Kirsch et a l, 2000). This data revealed a hydrophobic area of the type 1 receptor 
that fit into a hydrophobic pocket composed of residues of both BMP-2 monomers.
2.3 BMP receptors and their signaling
Like other members of the TGF-p family, BMPs are multifunctional proteins with 
effects on cell types not related to bone formation, e.g. epithelial cells, monocytes and 
neuronal cells (Cunningham et al., 1992; Hogan, 1996). In addition, BMPs are expressed 
not only in skeletal tissue, but also in many soft tissues. Consistent with these results, 
phenotypes of mice with mutated BMP genes revealed that they are multifunctional 
proteins that possess distinct roles in bone formation and many other morphogenic 
processes as shown in tables 2 and 3. Interestingly, several different mouse and human 
skeletal disorders (for example, short ear and brachipodism) are caused by a null 
mutation in BMP-5 (Kingsley e ta l, 1992) and GDF-5 (Storm et al., 1994), respectively. 
Double muscle cattle were found to have mutations in GDF-8 (McPherron et al., 1997). 
Hunter-Thompson type chondrodysplasia has been linked to mutations in human 
cartilage-derived morphogenetic protein (Thomas et al, 1996).
BMPs elicit their cellular effects by inducing specific heteromeric complexes of 
two related serine/threonine kinase receptors, type I receptor and type II receptor 
(Massague, 1998; Heldin et a l, 1997). Among the TGF-p family of receptors, the 
cDNAs encoding mouse activin and human TGF-P type II receptor were isolated first by 
an expression cloning strategy (Mathews et a l, 1991; Lin et a l, 1992). Both receptor 
types contain glycosylated cysteine-rich extracellular ligand-binding domains, short
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Table 2. Phenotypes of organisms with disruption of genes for BMPs
Mutated gene Phenotype
BMP-2 Embryonic death. Defects in amnion/chorion 
formation and cardiac development. (Zhang et al., 1996)
BMP-3 Viable. Increased bone mass. (Daluiski et al., 2001)
BMP-4 Embryonic death. Block of mesoderm formation. (Winnier et al., 1995)
BMP-5 Viable. Skeletal abnormalities, short ear, brachypodism. (Kingsley et al., 1992)
BMP-6 Viable. Delay in developing sternum ossification. (Solloway et al., 1998)
BMP-7/OP-1 Perinatal lethality. Severe defects in kidney and eyes. (Luo et al., 1995) 
Abnormalities of rib cage, skull and hindlimbs. (Dudley etal., 1995)
BMP5/7 Embryonic death. Retarded heart development. (Solloway et al., 1999)
BMP-8B Viable. Defects in spermatogenesis. (Zhao et al., 1996)
BMP-15 Viable. Increased ovulation rate leading to twins and triple
(GDF9B) births in heterozygotes and infertility in homozygotes. (Galloway et al., 2000)
GDF-5 Viable. Skeletal abnormalities, short ear, brachypodism. (Storm etal., 1994)
GDF-8 Viable. Increased skeletal muscle mass and body size. (McPherron etal., 1997)
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ActR-IA/ALK-2 Embryonic death. Block of mesoderm formation. (Gu et al., 1999)
BMPR-IA/ALK3 Embryonic death. Block of mesoderm formation. (Mishina et al., 1995)
BMPR-IB/ALK6 Viable. Defects in limb development. (Yi et al., 2000)
BMPR-n Embryonic death. Block of mesoderm formation. (Beppu et al., 2000)
ActR-nA & Embryonic death. Arrest at the egg cylinder stage
ActR-IIB and block of mesoderm formation. (Song et al., 1999)
Smads
Smadl Embryonic death. Defects in allantois formation. (Lechleider et al.)
Smad4 Embryonic death. Block of mesoderm formation. (Shard et al., 1998)
Smad5 Embryonic death. Defects in angiogenesis. (Chang et al., 1999)
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transmembrane domains and intracellular serine-threonine kinase domains (Massague, 
1998; Heldin et a l, 1997). A shared feature for type I receptors is that they have a 
glycine/serine residue-rich stretch in the juxtamembrane region, which is essential for 
type I receptor activation (Wrana et a l, 1994). Three mammalian BMPR-Is have been 
described to date (ten Dijke et al., 1994; Koenig et al., 1994), activin receptor-like kinase 
(ALK)2, BMPR-IA (also termed ALK3), and BMPR-IB (also termed ALK6). Initially, 
ALK2 was referred to as a type I receptor for TGF-P (Miettinen et al., 1994), or activin 
(ActR-I) (Attisano et a l, 1993), but recent studies suggest that ALK2 is very important in 
BMP signaling (Koenig e ta l, 1994; Macias-Silva et al., 1998; Armes e ta l, 1997). 
Different BMPs bind with different affinity to the type I receptors. For example, BMP-4 
binds preferentially to BMPR-A and -IB (ten Dijke et al., 1994), BMP-7 binds with 
higher affinity to ALK2 and BMPR-IB than to BMPR-IA (ten Dijke et a l, 1994), and 
GDF-5 binds preferentially to BMPR-IB, when compared with other type I receptors 
(Nishitoh et a l, 1996). Functional importance of BMPR-Is in bone formation was shown 
by the induction of chondroblast and osteoblast differentiation upon ectopic expression of 
mutant constitutively active BMPR-Is in mesenchymal precursor cells, and by 
observations that overexpression of dominant negative BMPR-Is interfered with BMP- 
induced osteoblast differentiation (Akiyama et al., 1997; Namiki et a l, 1997; Chen et al., 
1998; Fujii et al., 1999).
BMP type I and type II receptors have been found to be critically important for 
embryogenesis (Table 3) (Goumans et a l, 2000). Mice lacking ALK3 and BMPR-II are 
lethal due to absence of mesodermal development (Beppu et a l, 2000; Mshina et al., 
1995) and have a phenotype similar to BMP-4 knockout mice (Winnier et a l, 1995).
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ALK2-deficient embryos are much smaller than their normal littermates, and lack a 
morphologically discernible primitive streak and die prior to or during early gastrulation 
(Gu et a l, 1999). ALK6-deficient mice are viable and exhibit mainly appendicular 
skeleton defects (Yi et a l, 2000). Mice lacking ActR-II or ActR-HB are viable and were 
found to have a milder phenotype compared to a deficiency of one of their ligands. Some 
of ActR-II-deficient animals had mandibular hypoplasia and other skeletal and facial 
abnormalities (Matzuk et al, 1995). ActR-IIB knockout mice showed cardiac defects, 
abnormal anteroposterior and left-right body axis patterning (Oh et a l, 1997). However, 
ActR-II and ActR-IIB double-knockout homozygous showed strong lethal embryonic 
abnormalities; these mice were growth arrested at the egg cylinder stage and did not form 
mesoderm (Song et al., 1999). The stronger phenotype in the double knockout versus the 
single knockouts suggests a functional redundancy for ActR-II and ActR-IIB in the 
mouse.
BMPs exert their effects through complex formation with a heteromeric receptor 
complex. The complex consists of two type I and two type II polypeptides which are 
transmembrane serine/threonine kinases. The intracellular signaling pathways that are 
induced by the serine/threonine kinase receptors involve a family of signaling molecules 
called Smad proteins. At present, eight different Smad proteins have been identified in 
mammals. They can be divided into three subclasses: R-Smads (receptor-activated 
Smads), Co-Smads (common partner Smads), and anti-Smads (inhibitory Smads). Upon 
BMP receptor activation R-Smads (Smads 1, 5, and 8) are phosphorylated by the 
activated BMP type I receptor (Massague, 1998; Heldin et a l, 1997). Activated R- 
Smads can form a heteromeric complex with Co-Smad (Smad4) (Lagna et a l, 1996) and
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translocate into the nucleus. Within the nucleus, R-Smads/Co-Smad complexes can 
directly bind to specific sequences in the promoters of BMP target genes and regulate the 
transcription of those genes (Massague et a l, 2000; ten Dijke et al., 2000).
Gene disruption of Smad genes in mice has revealed specific and developmental 
functions of Smads that are implicated in BMP signaling. Whereas mice lacking Smadl, 
Smad4, or Smad5 are developmentally arrested, Smad6 mice make it to term as 
summarized in table 3 (Goumans et al., 2000). To study the role of Smads in cartilage 
and bone formation, conditional knockouts in mesenchymal precursor cells and 
osteoblasts are eagerly awaited.
2.4 BMP localization
Although BMPs were originally isolated and identified from bone, it was soon 
discovered by a variety of studies that BMPs are expressed in most other tissues of the 
human body. Expression has been found not only in many adult tissues, but also 
throughout embryonic development (Wozney, 1998; Hogan, 1996). During 
embryogenesis BMPs serve as important inductive signals for tissue development and 
have been shown to have a key role in development of the musculoskeletal system, the 
nervous system, the heart, kidney, skin, eyes, and teeth. After birth, the BMPs play roles 
in tissue repair and regeneration. Many analytical procedures have been utilized to 
localized OP-1. The first indication that OP-1 had a more widespread localization than 
bone occurred when OP-1 cDNA was found in a cDNA library generated from 
hippocampus (Ozkaynak et al, 1990). Subsequently, the mRNA was extracted from a 
variety of adult mouse tissues and evaluated for the presence of OP-1 mRNA (Ozkaynak 
et al., 1991; Ozkaynak et al, 1992). Large amounts of OP-1 mRNA were found in the
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kidney and significant amounts were found in the bladder, adrenal tissue, brain, and 
calvaria. No detectable OP-1 mRNA was found in the heart and liver. Mouse embryos 
were also evaluated and found to contain OP-1 mRNA in multiple organs at levels that 
varied depending upon the time after conception. In gene knockout studies, mice lacking 
the OP-1 gene displayed severe defects in the developing kidney and eye and appeared 
polydactyl (Karsenty etal., 1996). These studies clearly demonstrated that the absence of 
OP-1 disrupts the cellular interactions required for the growth and development of these 
organs. Finally immunolocalization studies have shown that the OP-1 protein is also 
present in multiple tissues in both adult animals and during embryonic development.
2.5 Biological activities of bone morphogenetic proteins
The biological activities of BMPs have been evaluated in vivo using a variety of 
animal models and in vitro using a variety of cell lines (Azari et a l, 2001; Schmitt et al,
1999). Because of their discovery in bone, most of these studies have been done using 
bone cells and bone defect animal models. Related tissues such as cartilage and other 
hard tissues such as dentin have also been examined. More recently the biological 
activities are being evaluated in soft tissues, particularly brain, kidney, and muscle.
The rat subcutaneous bone formation assay has been the standard method used to 
evaluate the osteoinductive potential of BMPs. Implantation of purified recombinant 
BMP with bone collagen matrix in subcutaneous sites in rats induces a sequence of 
cellular events that results in the formation of new bone complete with bone marrow 
elements (Sampath et a l, 1994). More recently the in vivo athymic mouse bioassay and 
the in vitro bioassay using human periosteal (HPO) cells have been utilized to assess the 
osteoinductivity of human demineralized bone matrix (Zhang et al., 1997). During the
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osteoinductive process the first step is the recruitment by the BMP of nearby 
mesenchymal stem cells into the collagen matrix. The BMP stimulates the stem cells to 
proliferate and then triggers their differentiation into chondrocytes in 5 to 7 days. 
Cartilage is formed and on capillary invasion, the chondrocytes hypertrophy, become 
calcified, and osteoblasts appear in the implant site. Newly formed bone is present in 9 to 
12 days. Subsequently, the bone is remodeled extensively and becomes occupied by 
ossicles filled with bone marrow elements in 14 to 21 days. This cellular process is 
referred to as endochondral bone formation. Osteoinductive BMPs are also observed to 
form bone by intramembraneous bone formation whereby the BMP triggers the 
mesenchymal cells to differentiate directly to osteoblasts and thus bypass the cartilage 
stage.
The critical activity of implanted BMPs during the bone formation process occurs 
at the beginning of the biological cascade. These activities involve the interactions with 
the mesenchymal cells including chymotaxis, proliferation and differentiation into bone 
and/or cartilage cells. The subsequent steps appear to rely on the local induction of a 
range of factors, including other BMPs. OP-1 has recently been shown to induce 
numerous growth factors and multiple BMPs during the bone induction process (Patel et 
al., 2001). Additional support for the action of OP-1 throughout the bone formation 
process is also provided by in vitro studies (Asahina et al., 1993, 1996; Cheifetz et al., 
1996; Kitten et al., 1995; knutsen et al., 1993; Maliakal et al., 1994). These data have 
demonstrated that OP-1 has multiple chondrogenic effects. This protein can induce the 
chondrogenic phenotype in chondrocyte precursor cells and induce chondrogenesis in
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non-cartilage stem cells. OP-1 also promotes re-expression of chondrocyte phenotype by 
dedifferentiated articular chondrocytes and enhances mature chondrocyte characteristics 
in normal articular chondrocytes.
To date many studies have been published evaluating the efficacy ofBMPs in 
conjunction with matrix materials for local repair of bone defects (Pecina et al, 2001). 
These include most long bones, various cranialfacial bones and the spinal column. For 
the most part these studies have utilized either OP-1 or BMP-2 but recent studies have 
also examined GDF-5 (Spiro et al., 2000). In general, the BMPs have been shown to be 
highly efficacious in repairing bones in many animal species, including rat, rabbit, dog, 
sheep, goat, monkey and baboon. More recently OP-1 and BMP-2 have also been shown 
to be efficacious in initial testing in humans (Fiedlaender et al., 2001; Geesink et al, 
1999; Groenveld e ta l, 2000; Riedel et al., 1999).
Cartilage is observed as an intermediate step during the BMP-induced bone 
induction process. Furthermore in vitro studies have demonstrated that BMPs can 
promote chondrogenic differentiation, maturation, and maintenance of chondrocyte 
phenotype and BMPs have been localized to cartilage (Chubinskaya et al., 2000). These 
observations suggested that BMPs might be useful for healing cartilage. Studies have 
been reported evaluating BMPs in in vivo models of both osteochondral and chondral 
defects. Both OP-1 and BMP-2 formulated with collagen have been evaluated in 
osteochondral defects and shown to be efficacious (Cook et a l, 1996; Sellers et al., 1997,
2000). These studies have demonstrated that the BMPs can improve both the bone and 
cartilage healing in the defects, but the repair appears to be variable among species and 
the specific type and stability of the cartilage has not fully been evaluated. In one sheep
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study using a chondral defect, OP-1 was shown to induce substantial healing (Jelic et al., 
2001). In this model which used mini-osmotic pumps to slowly deliver the OP-1 into the 
articular joint, no healing was observed in the control defects.
Brain tissue has been one of the first non-bone tissues investigated for the 
biological activities of BMPs (Helm etal., 2000). In vitro studies using OP-1 have 
demonstrated that this BMP increased expression of the adrenergic phenotype in neural 
crest cells and OP-1 regulated expression of LI and neural cell adhesion molecules in a 
neural cell line. In further studies it was discovered that OP-1 selectively induces 
dendritic growth in cultured rat neuron and the dendrites correctly segregate, modify 
cytoskeletal and membrane proteins, and form synaptic contacts of appropriate polarity 
(Wither et al., 2000). Based on these observations OP-1 was evaluated in vivo for the 
repair of nerve tissue in stroke models. In rat models of cerebral hypoxial ischemia OP-1 
was injected intracisternally into the brain and shown to protect against damage, as well 
as to facilitate the recovery from damage caused by experimental stroke (Liu et al.,
2001).
The biological activities ofBMPs have also been evaluated using the kidney 
(Reddi, 2000). This organ has been identified as the major site for synthesis of OP-1 
during embryonic development as well as in adulthood. In addition, numerous in vitro 
studies have suggested that OP-1 is required for metanephric mesenchyme differentiation 
and can affect kidney cells in culture. The results from both chronic and acute disease 
models in rats have demonstrated that intravenous administration of OP-1 can protect 
against damage as well as facilitate recovery from this damage (Vukicevic et al., 1998).
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3. PURPOSE OF THIS STUDY
3 .1 Establishment of quantitative in vitro assay for evaluating osteoinductivity of DBM
Previous studies have shown that the osteoinductive activity of DBM was 
predominantly attributable to BMPs present in the bone matrix (Sampath et al., 1992; 
Urist et al, 1979). The osteoinductivity of DBM depends on not only the quality of 
BMPs but also the quantity of BMPs in the bone matrix (Vukicevic et al., 1989; Sampath 
et a l, 1992). The osteoinductive capability of DBM is a crucial quality factor that should 
be taken into account prior to distribution.
Currently, there are no standard methods for determining the osteoinductivity of 
demineralized bone matrices, or similar implant materials. The use of DBM in the 
induction of new bone formation has been assessed using in vivo animal based and in 
vitro cell culture based bioassays. In vivo animal based bioassays are expensive and take 
at least 4 weeks. Although several in vitro bioassays have been utilized for assessing 
osteoinductivity of DBM, the results generally require at least 7 days. Research 
endeavors have been made to develop a facile and expeditious assay for detection and 
quantitation of osteoinductive proteins and to correlate that with the osteoinductivity of 
bone materials. The current study is designed to establish a method of assessing 
osteoinductivity of DBM using quantitative in vitro bioassay. Furthermore, this study is 
directed at determining the relationships between residual calcium contents and particle 
size of DBM and the extractability of BMP-4 from those DBM samples. The effects of 
donor age and gender on the extractability ofBMP-4 from DBM were also investigated.
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3.2 Gene expression analysis of osteogenic differentiation
Osteoblasts are specialized cells capable of producing bone matrix. The transition 
from preosteoblast to mature osteoblast occurs in distinguishable stages and has been 
extensively investigated. Multipotential stem cells undergo successive stages of 
differentiation with decreasing proliferation potential, giving rise to committed 
preosteoblasts. Subsequently, preosteoblasts differentiate into mature osteoblasts, which 
deposit the necessary components to form the bone matrix that is then mineralized.
The recently development of cDNA gene expression array technique allows the 
analysis of the expression levels of hundreds to thousands of genes simultaneously, 
providing an effective tool for large-scale gene expression studies (Schena et al., 1996). 
The current research used gene array technology to screen alterations in gene expression 
during differentiation of human periosteal cells to an osteoblast like phenotype. In this 
study, the expression of 96 genes in human periosteal cells in response to DBM- 
conditioned media was examined using human osteogenesis gene array. The results 
obtained from the cDNA gene expression array analysis were validated on HPO/LN- 
SH01 cell line using RT-PCR.




Sterile human DBM, particle size ranges from 250 to 850 microns, was kindly 
provided by LifeNet, Virginia Beach, Virginia. Bone, procured by LifeNet staff from 
cadaver donors shortly (less than 24 hours) after death, was stored frozen at -84°C until 
processed. For processing, the bone was thawed at room temperature, mechanically 
crushed to remove soft tissues such as bone marrow and periosteum, ground using a 
Telsa Analytical Bone Mill, sized (250-710 micron), and refrozen.
2. PREPARATION OF BONE MATRIX WITH VARIABLE RESIDUAL CALCIUM
Ground bone matrix (particle size from 250 to 850 micron) provided by LifeNet 
was demineralized by exposure to 0.5 N hydrochloric acid (HC1) (100 mg DBM to 10 ml 
0.5 N HC1). Demineralized bone matrices of variable calcium content were acquired by 
removing bone matrix from the acid at various time intervals; i.e., 45, 90, 135, 180 
minutes, and then following a prolonged demineralization process (300 minutes). The 
variably demineralized bone matrices were washed, freeze dried, and stored at -80°C. 
The demineralization process was performed aseptically with no additional sterilization 
of the DBM before use in the bioassays.
3. PREPARATION OF DBM WITH DIFFERENT PARTICLE SIZES
Freeze dried human cortical and cancellous bone was ground by impact 
fragmentation and separated using a series of variably sized sieves. Samples were 
collected according to the following particle size ranges: <250 micron, 250 to 355 
micron, 355 to 550 micron, 550 to 710 micron, and 710 to 850 micron. Samples were
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then exposed to 0.5 N HC1 such that solubilized calcium phosphate salts did not 
neutralize the acid solution. The demineralization process was monitored by the pH of 
the demineralization solution using pH meter. The pH of the demineralization solution 
was approximately 2.4 at the beginning of the demineralization process due to the 
buffering ability of the calcium phosphate salts being solubilized from the bone matrix.
As the demineralization process continued, the buffering ability of solubilized salts 
decreased. The demineralization process was stopped when the pH of the 
demineralization solution dropped to pH 1. Based on the LifeNet’s production, the 
residual calcium content of DBM reached 2%.
4. QUANTITATIVE DETERMINATION OF CALCIUM
Residual calcium contents of ground bone matrix were determined using a 
modification of the DMA calcium assay kit (DMA, Inc., Arlington, Texas). This DMA 
calcium procedure is based on the cresolphthalein complexone reaction as modified by 
Baginski (Baginski et al., 1973). In general, calcium reacts with cresolphthalein 
complexone to form a colored complex that is measured spectrophotometrically at 570 
nm and is proportional to the amount of calcium present. The variably demineralized 
bone matrices were dissolved in 4.0 ml of 1 N HC1 at 90°C overnight. 50 pi of sample or 
appropriate standard were mixed with 4.0 ml of calcium working reagent. The pH of 
each mixture was approximately equivalent. Calcium working reagent was prepared by 
mixing equal amounts of calcium color reagent and calcium base reagent. Calcium color 
reagent contains cresolphthalein complexone and calcium base reagent comprises 
diethylamine and potassium cyanide. Absorption was measured at 570 nm. Calcium 
concentrations were calculated from a standard curve using known concentrations of
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DMA calcium standard. The calcium content was expressed as weight percent calcium 
of bone matrix dry weight.
5. PREPARATION OF PROTEIN EXTRACTS OF DBM
DBM samples were extracted by collagenase digestion as previously described by 
Jortikka (Jortikka et al., 1993). Generally, demineralized bone matrices with particle size 
ranging from 250 to 850 micron were digested with type I collagenase (Sigma Chemical 
Co., St. Louis) in 200 mM Tris-HCl buffer, pH 7.2 with 3 mM CaCl2, 3mM MgS04, 20 
mMNaCl, 3 mM N-ethylmaleimide (NEM), 0.1 mM phenylmethanesulfonyl fluoride 
(PMSF), and 0.1 mM benzamidine-HCl at 37°C for 24 hours with continuous shaking. 
The mixture was then centrifuged and the supernatant dialyzed against distilled water at 
4°C overnight. The dialysate was recovered and stored at -20°C until assayed for BMP 
quantity.
6. GEL ELECTROPHORESIS
For gel electrophoresis, samples of DBM protein extracts were analyzed on 4 to 
15% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
according to the method of Laemmli (Laemmli et al., 1970). Molecular weight standards 
were also included. Following electrophoresis, gels were stained with Bio-Safe 
Coomassie blue stain.
7. WESTERN BLOT ANALYSIS
To determine the presence of BMP-4 in protein extracts of DBM, samples of 
protein extracts, together with rhBMP-4 (R&D Systems, Minneapolis, MN), in Laemmli 
sample buffer were applied to 4 to 15% gradient gels and subjected to SDS-
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polyacrylamide gel electrophoresis. Western blot analysis was carried out after proteins 
were electrophoretically transferred to PVDF membranes (Bio-Rad, Hercules, CA). 
Nonspecific hybridization was blocked by incubating the membranes in PBST 
(Phosphate buffered saline with 0.1% Tween-20) containing 3% blocker for 1 hour at 
room temperature. The membranes were then washed three times with PBST for 5 
minutes per wash and placed in PBST containing 1% BSA (Bovine serum albumin) and 
mouse anti-BMP-4 monoclonal antibody (Chemicon International, Temecula, CA) at a 
concentration of 1:2000 for 1 hour at room temperature. The antibody was removed and 
the membranes were then washed three times in PBST and incubated in PBST with 1% 
BSA and goat anti-mouse IgG conjugated with horseradish peroxidase (Bio-Rad, 
Hercules, CA) at a concentration of 1:5000 for 1 hour at room temperature. Subsequently 
the membranes were washed three times in PBST and poured off PBST from the 
membranes and then protein bands were visualized by placing the membrane in Opti- 
4CN (4-chloro-1 -naphthol) substrate solution until the desired level of signal is attained. 
The colorimetric detection was accomplished by rinsing the membrane in deionized H2 O 
for 15 minutes.
8. QUANTITATIVE BMP-4 IMMUNOASSAY (ELISA)
Quantitative sandwich enzyme-linked immunosorbent assay was employed to 
determine BMP-4 content in protein extracts of DBM using a commercially available kit 
(R&D Systems, Minneapolis, MN; sensitivity, 1.04 pg/ml; range, 31.2 to 2,000 pg/ml). 
Briefly, 200 pi of sample or appropriate standard as shown in Figure 2 were added to 
each well of a 96 well-microtiter plate precoated with anti-BMP-4 monoclonal antibody 
and incubated for 2 hours at room temperature. Following a wash to remove any
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unbound antibody-enzyme reagent, 200 |il of a substrate solution was added to the well 
and incubated for 30 minutes at room temperature. The color development was stopped 
with 50 pi of 2 N sulfuric acid and the intensity of the color was measured using a 
microplate reader (Multiskan Ascent, Labsystems, Franklin, MA) at 450 nm. The 
concentration of BMP-4 in sample extracts was determined by comparing the optical 
density of the sample to a standard curve as illustrated in Figure 3.
9. IN VIVO ATHYMIC MOUSE BIOASSAY
Eight to ten weeks old male athymic mice were anesthetized and tranquilized with 
intraperitoneal injection of sodium Phenobarbital (0.44 ml/kg, Somnifer, Richmond 
Veterinary Supply Company, Richmond, Virginia) and acepromazine (1.1 mg/kg, 
PromAce, Ayerst Laboratories, Inc., New York) respectively. The area of the incision 
site was disinfected with 70% isopropyl alcohol and draped for sterile surgery. A 1 cm 
long incision was made along the dorsal midline through the skin and subcutaneous tissue 
near the gluteal region. The incision was made using a No. 10 blade (American 
Scientific Products, Illinois) on a scalpel handle size 3. Blunt dissection was made 
between the skin and the tissue below with small tapered scissors. The fascia of the 
longissimus dorsi muscle was pulled up with forceps and incised over the implantation 
sites with small pointed dressing scissors. Muscle pouches were created bilaterally within 
the longissimus dorsi muscle by blunt dissection. DBM rehydrated with saline (30 
minutes before surgery) was packed into the muscle pouch. The muscle pouch was 
closed with sutures of 6-0 polypropylene. The skin was closed with sutures of 6-0 
polypropylene and 9 mm Michael wound clips applied on top of the sutures for protecting


























Figure 2. BMP-4 standard. Recombinant human BMP-4 was used to produce a dilution series. The 2000 
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Figure 3. BMP-4 immunoassay (ELISA) standard. The concentrations of BMP-4 standards are 
31.5, 62.5, 125, 250, 500, 1000, 2000 pg per milliliter. The absorbance was measured at 450 nm.
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disruption of the sutures. After 4 weeks of implantation, the implants were isolated from 
the muscle pouches and cleaned of excess tissue.
10. HISTOLOGICAL EVALUATION
The explants from each implantation site were fixed in 10% neutral phosphate 
buffered formalin for at least 24 hours, decalcified in 10% formic acid solution, 
embedded in paraffin, sectioned, and subsequently stained with hematoxylin and eosin 
prior to examination by light microscopy. The areas of new bone and total bone (new 
bone and implant bone) were measured using histomorphometric analysis. The 
percentage of new bone formation was expressed relative to the total cross-sectional area 
measured.
11. INITIATION OF HUMAN PERIOSTEAL CELL CULTURES
Periosteum from an adult female (55 years old) femur was acquired during routine 
tissue procurement by LifeNet staff with consent of the next kin. The periosteum was 
washed 3 times with Minimum Essential Medium Eagle (MEM, Sigma Chemical Co, St 
Louis, M4526) containing 200 units/ml penicillin and 100 pg/ml streptomycin, cut into 
1.0 mm x 1.0 mm pieces, and placed with the internal stratum osteogenicum layer facing 
toward the surface of the T-25 flasks. The preparation was cultured in alpha-MEM 
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/ml) 
/streptomycin (50 pg/ml) in a 5% CO2 incubator at 37°C. The outgrowing cells were 
combined and transferred into T-75 flasks by detachment with a 0.025% trypsin and 
0.05% EDTA solution and cultured in the same media and incubator. When cells reached 
confluence, they were split into new T-75 flasks at ratios of 1:4.
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12. CRYOPRESERVATION OF HPO/LN-SHOl CELLS
Passages 2-4 human periosteal cells were cryopreserved to establish a cell bank. 
Cells were treated with trypsin (0.025% trypsin in 0.05%EDTA solution), neutralized 
with MEM supplemented with 10% FBS and sedimented by centrifugation at 1,000 rpm 
for 5 minutes. Cell pellets were resuspended in freezing solution (20% FBS and 10% 
DMSO in MEM) at a concentration of 1 x 106 cells/ml and 1 ml aliquots were placed into 
sterile ampules. Ampules containing cells in a styrofoam box were placed into 
refrigerator (4°C) for 2 hours, transferred into a freezer (-20°C) for 8 hours, a -70°C 
freezer overnight, and finally transferred to -140 °C for long term storage.
13. CELL THAWING AND CULTURE
For experiment use, ampules of frozen cells were quickly removed from the 
-140°C storage freezer, thaw in a 37°C water bath for 2 minutes and the cells immediately 
transferred into T-75 flasks with 20 ml of MEM supplemented with 10% FBS, and put 
into a 37°C, 5% C02 incubator. When cell cultures reached confluence, HPO/LN-SHOl 
cells were treated with trypsin and split 1:4 into new T-75 flasks until sufficient cell 
populations were obtained for experiments.
14. CULTURE OF CELLS USED IN ALKALINE PHOSPHATASE ASSAY
When appropriate numbers ofHPO/LN-SH-01 were acquired, cells were treated 
with trypsin, neutralized with 10% FBS, and sedimented by centrifugation at 1,000 rpm 
for 5 minutes. Cell pellets were resuspended in small volumes of MEM supplemented 
with 10%FBS and pooled into one T-75 flask. Pooled cell suspensions were mixed well 
by trituration and counted using a hemocytometer. Cells were seeded into T-25 flasks at
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
40
6.25 x 105 cells per flask (or 2.5 x 104 cells/cm2). These cell cultures were maintained in 
10 ml of alpha-MEM supplemented with 10% fetal bovine serum (FBS) and penicillin 
(100 units/ml) /streptomycin (50 pg/ml) until reaching confluence. The alpha-MEM 
medium was then changed to 10 ml of Dulbecco’s Modified Eagles’ Medium (DMEM, 
Sigma Chemical Co., St. Louis, D8788) supplemented with 2% FBS. Various 
concentrations of DBM condition media (DBM-CM) were added into randomly assigned 
flasks immediately following changing of the medium to DMEM.
15. ALKALINE PHOSPHATASE ASSAY
Alkaline phosphatase is a membrane bound enzyme that is present in many cell 
types but is most abundant in osteoblasts. Alkaline phosphatase is a specific marker of 
the osteoblastic phenotype and thought to be of importance in the mineralization process 
by increasing the concentration of inorganic phosphate resulting in precipitation of 
calcium-phosphate crystals. The mesenchymal cell induction process typically associated 
with osteoinductivity of demineralized bone materials is monitored by changes in 
alkaline phosphatase activity of cells being studied. According to Zhang (Zhang et al., 
1997), nonosteoinductive (HPO) cells express low level of alkaline phosphatase activity, 
whereas osteoinducing cells express high level of alkaline phosphatase activity. This 
protein can be visualized by histochemical alkaline phosphatase staining assay. The 
alkaline phosphatase activity can also be quantified by incubating cell lysate with p- 
nitrophenyl-phosphate then measuring absorbance in a spectrophotometer or microplate 
reader at 405 nm. This alkaline phosphatase activity assay is facile and reliable when 
performed in triplicate in 96-well plates.
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Alkaline phosphatase staining assay was performed using the Sigma Diagnostics 
Alkaline Phosphatase kit (Catalog No.86-2, Sigma Diagnostics, Inc., St. Louis) as 
directed by the manufacturer. Briefly, cell layers were rinsed with phosphate buffer 
saline (PBS), fixed with citrate-acetone-formaldehyde fixative solution at room 
temperature for 30 seconds, and then stained with alkaline-dye mixture at room 
temperature for 15 minutes. Naphthol AS-BI alkaline solution and fast red violet B 
(FRV-alkaline solution) were utilized for determining the enzyme activity. Slides were 
then counterstained with hematoxylin solution, gill No. 3 and evaluated using light 
microscopy.
Alkaline phosphatase activities were determined using a modification of the 
procedure described by Wolfinbarger and Zheng (Wolfmbarger et al., 1993). Basically, 
treated cells were quickly rinsed twice with 3 ml deionized water, scraped with a cell 
scraper (Fisher Scientific, Pittsburgh, PA) in 3 ml deionized water and sonicated at 30% 
intensity for 30 seconds. Next 200 pi aliquot samples were transferred to each well of a 
96-well plate and were mixed with 40 pi of 100 mmol/ml p-nitrophenyl phosphate in 
0.15 M 2-amino-2-methyl-1 -propanol buffer, pH 10.4, and incubated for 20 minutes at 
37°C. The reaction was stopped by the addition of 10 pi of 10 N NaOH into each well 
and absorbance determined at 405 nm using a microplate reader (Multiskan Ascent, 
Labsystems, Franklin, MA). Alkaline phosphatase activity (expressed as pmols of 
converted p-nitrophenol/min) was normalized by total protein content. Protein 
concentrations of the samples were determined by using the BCA protein assay (Pierce, 
Rockford, IL). The Alkaline phosphatase activities were expressed as pmols of p- 
nitrophenol/min/pg of protein).
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16. STATISTICAL ANALYSIS
The data are expressed as means with error bars representing standard error of the 
mean (SEM). Analysis of variance (ANOVA) was used to determine the significant 
differences among treatment groups. Tukey-type multiple comparison tests were used for 
comparing means of more than two groups in one way ANOVA analyses. Correlation 
between extractable BMP-4 level and osteoinductive capability of DBM was analyzed by 
linear regression analysis (SPSS 10.00); A P value of less than 0.05 was considered to be 
statistically significant.
17. RNA ISOLATION AND MICRO ARRAY ANALYSIS
Total cellular RNA was isolated from HPO cells on days 7 in the presence or 
absence of 100 pg/ml DBM-CM using the RNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. The purity and amount of isolated RNA 
were assessed by spectrophotometric measurement at 260 and 280 nm. Equal amounts of 
total cellular RNA (5 pg) was reverse transcribed to cDNA at 42°C for 90 minutes in a 
volume of 20 pi containing the following reagents: 3 pi GEA primer mix (Buffer A); 4 pi 
5x GEA labeling buffer (Buffer BN); 1 pi RNase inhibitor (Promega, Madison, WI), 2 pi 
1 mM Biotin-16-dUTP (Roche), and 50 U MMLV reverse transcriptase (Promega, 
Madison, WI). After terminating the reaction by adding 2 pi lOx stop solution (Buffer 
C), the biotin labeled cDNA probes were denatured by heating at 94°C for 5 minutes and 
chilled quickly on ice.
Human osteogenesis GEArray Q series cDNA expression arrays (SuperArray 
Bioscience, Frederick, MD) nylon membranes, containing over 96 cDNA fragments from 
genes associated with bone development, were used for hybridization studies. The arrays
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were prehybridized with 200 pg of the heat-denatured salmon sperm DNA (Invitrogen/ 
Life Technologies, Carlsbad, CA) and 2.0 ml GEAhyb hybridization solution 
(SuperArray Bioscience, Frederick, MD) for 2 hours at 60°C. The denatured cDNA 
probes were added to the GEAhyb hybridization solution and left to hybridize with the 
array nylon membranes overnight with continuous agitation at 60°C. Washes were done 
twice at 60°C in 2x SSC with 1% sodium dodecylsulfate (SDS) for 15 minutes and twice 
at 60°C in 0. lx SSC with 0.5% SDS for 15 minutes with continuous agitation. The 
membranes were blocked for 40 minutes by incubating with 2 ml GEA blocking solution 
Q at room temperature and incubated with a 1:7500 dilution of alkaline phosphatase- 
conjugated streptavidin for 10 minutes. Subsequently, membranes were then washed 
four times in lx buffer F (SuperArray Bioscience, Frederick, MD) and rinsed twice with 
lx AP-assay buffer G (SuperArray Bioscience, Frederick, MD). Visualization was 
accomplished using 1.0 ml CDP-star chemiluminescent substrate (SuperArray 
Bioscience, Frederick, MD) to sufficiently cover the membranes for 2 minutes at room 
temperature. The membranes were placed on Kodak BioMax maximum resolution (MR) 
autoradiography film (Kodak, Rochester, NY) at room temperature. Appropriately 
exposed autoradiographs of the membranes were quantified by translumination of the X- 
ray film using a scanner (Hewlett-Packard).
The image obtained using a scanner was converted into a gray scale TIFF file.
The TIFF image was then converted to numerical data by using ScanAnalyze software, 
developed by Michael Eisen of Standford University. Images were gridded to locate the 
spot corresponding to each gene. Following gridding, information on each spot, 
including intensities, background intensities and ratios, was extracted using ScanAlyze
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and presented as a Microsoft Excel file. Ratios were ultimately used to determine 
differentiation of gene expression. Genes with ratio number above 2 or under 0.5, i.e., 2 
fold induction or repression, were selected and subjected to further analysis. The array in 
this study contains pUC18 as a negative control and also contains GAPDH, cyclophilin 
A, RPL13A, and P-actin as positive controls, which were averaged to create a 
normalization value for each array. Each signal was normalized against the signal of a 
housekeeping gene in order to compare data from two different arrays. The relative 
specific intensity within each signal was calculated as the ratio of the density of each 
signal in the DBM-CM treatment divided by the density of corresponding signal in the 
control (without DBM-CM addition) using GEArray Analyzer software (SuperArray 
Bioscience, Frederick, MD).
18. POLY (A)+ RNA PURIFICATION AND RT-PCR
Poly (A)+ RNA was isolated from HPO cells that were cultured with or without 
DBM-CM for 0, 4, 7, 10, and 14 days using the QuickPrep Micro mRNA Purification Kit 
following the manufacturer’s instructions (Amersham Biosciences, Piscataway, NJ). For 
RT-PCR analysis, 150 ng poly (A)+ RNA was reverse transcribed to cDNA at 42°C for 
60 minutes in a volume of 20 pi containing the following reagents: 0.5 mM dNTP mix; 
lx ImProm-II Reaction Buffer; 6 mM MgCL; and 20 U of Recombinant RNasin 
Ribonuclease Inhibitor. The reactions were then terminated at 70°C for 15 minutes.
Aliquots of the cDNA were amplified in 100 pi of a PCR reaction mixture which 
contained 1 pM primer sets, lx thermophilic polymerase reaction buffer (BioRad) (lOx = 
200 mM Tris-HCl, pH 8.4, and 500 mM KC1), and 5 U of iTaq DNA polymerase 
(BioRad). Primers for biglycan, collagenl4Al, and GAPDH were prepared based on
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previously described sequences as follows: biglycan (sense: 5’- 
CCCTCTCCAGGTCCATCCGC-3’ and antisense: 5’-
GAGCTGGGTAGGTTGGGCGGG-3 ’, Chen etal. 2002); collagenMAl (sense: 5’- 
TGGACAGAACCAGCTACAACCATAGT-3’ and antisense: 5’- 
GGAGACGCTGACGCCTTCGCCATCCGT-3Meirowitz etal. 2002); and GAPDH 
(sense: 5 ’ - ACC AC AGTCC ATGCC ATC AC-3 ’ and antisense: 5’- 
TCCACCACCCTGTTGCTGTA-3 ’, Locklin et al. 2001). All primers were purchased 
from Integrated DNA Technologies, Coralville, IA. Amplifications were performed in a 
thermocycler. DNA amplification included an initial denaturation at 94°C for 2 minutes, 
followed by 25 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 1 
minute, and extension at 72°C for 2 minutes. The final cycle included 5 minutes for 
extension. Aliquots of the PCR products were diluted 1:10 and then analyzed by 
electrophoresis in 2% agarose gel stained with Gel star Stain (Clare Chemical Research, 
Inc., Dolores, CO). PCR markers (Promega, Madison, WI) were used as molecular 
weight markers. 1.2 kb Kanamycin RNA combined with oligo (dT)is primer served as a 
positive control. As a negative control, PCR amplification without either RT or poly (A)+ 
RNA was carried out. No PCR products were obtained in these experiments for all pairs 
of primers.
19. HUMAN SUBJECTS
According to the office for human research protections website, 
http ://ohrp. osophs, dhhs. gov/humansubi ects/assurance the use of human tissue in this 
dissertation research does not fall under their guidance. They define human subjects as a 
living individual about whom an investigator (whether professional or student)
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conducting research obtains data through intervention or interaction with the 
individual(s), or identifiable private information. This tissue used in the dissertation 
research does have consent from the donor’s family as required in LifeNet policy, POL- 
RD-001.002.
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Table 4. Sequences of human oligonucleotide primer pairs used in RT-PCR
Gene Sequence Product length (bp)
BGN (sense) 5 ’ -CCCTCTCC AGGTCCATCCGC-3 ’ 500
(antisense) 5’-GAGCTGGGTAGGTTGGGCGGG-3’
COL14A1 (sense) 5 ’-TGGACAGAACCAGCTACAACCATAGT-3 ’ 315
(antisense) 5 ’ -GGAGACGCTGACGCCTTCGCCATCCGT-3 ’
GAPDH (sense) 5 ’-ACCACAGTCCATGCCATCAC-3 ’ 500
(antisense) 5’-TCCACCACCCTGTTGCTGTA-3’
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RESULTS
1. QUANTITATIVE IN VITRO BIOASSAY
1.1 Presence of BMP-4 in protein extracts of DBM
The present study was undertaken to determine whether BMP could be extracted 
and identified using Western blot analysis. The protein extracts of DBM were separated 
on SDS-PAGE, transferred to PVDF membranes, and probed with a monoclonal antibody 
directed against human BMP-4. A serial dilution of recombinant human BMP-4 served 
as a positive control. Western blot analysis displayed the detection of a single band of 18 
kDa that was consistent with that of BMP-4 (Figure 4). The results indicate the presence 
of BMP-4 in the protein extracts of DBM. However, the levels of extractable BMP-4 
were unable to be accurately quantified using Western blot analysis.
1.2 The effect of residual calcium on extractability of BMP-4
The quantitative BMP-4 in vitro assay was utilized to study the effect of residual 
calcium contents on the extractability ofBMP-4 from DBM. Equivalent amounts (100 
mg) of DBM with different levels of residual calcium were extracted by collagenase 
digestion. Extractable BMP-4 levels were measured using BMP-4 ELISA, and the results 
were compared and demonstrated in Figure 5. Results are representative of at least two 
independent experiments.
As shown in Figure 5, the data from samples of bone matrix containing 18% to 
0.05% residual calcium indicated that as the residual calcium level decreased, the 
extractability ofBMP-4 increased. The level of extractable BMP-4 was unable to be 
detected in non-demineralized bone matrix (25% residual calcium) with this BMP-4
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Figure 4. Western blot analysis of protein extracts from human demineralized bone and recombinant 
human BMP-4. Extracts were prepared as delineated in Materials and Methods and then 
electrophoresed on SDS-gels. After electrophoresis, protein samples were transferred to PVDF 
membranes and stained with anti-BMP-4 monoclonal antibody. Lanes 1-6: rhBMP-4 64, 32, 16, 8, 4, 
and 2 ng, respectively; Lane 7: protein extracts of DBM; Lane 8: protein extracts of DBM spiked with 
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Figure 5. BMP-4 levels in protein extracts of demineralized bone particles containing variable levels 
of residual calcium. DBM with different levels of residual calcium were extracted and extractable 
BMP-4 levels were determined using BMP-4 ELISA. The residual calcium levels were measured 
using the DMA Calcium assay. Particle sizes of DBM used here were 250 to 850 microns. Data are 
shown as means with error bars representing standard error of the mean (SEM) (n=3).
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ELISA (data not shown). On the other hand, the DBM demineralized to a residual 
calcium content of 0.05% produced the highest level of extractable BMP-4 among the 
variable residual calcium level group tested. In general, the relationship between the 
residual calcium contents of 25 (non-demineralized bone) to 0.05 weight percent and the 
extractability ofBMP-4 from DBM can be expressed as: Y = -359.23 X + 2198.7, (R = 
0.9745), where Y is the extractable BMP-4 level of DBM and X is the residual calcium 
content of DBM.
To further normalize and compare the extractability ofBMP-4 of variously 
demineralized bone matrices, the percentages of the highest extractability ofBMP-4 were 
calculated and compared. As illustrated in Table 5, the maximum extractability of BMP- 
4 was accomplished by bone matrix containing 0.05% residual calcium. The 0.8% 
residual calcium bone matrix achieved 73% of the maximum extractable BMP-4 level, 
the 1.8% residual calcium bone matrix attained 56% of the maximum extractable BMP-4 
level, the bone matrix demineralized to 9% calcium revealed 26% of the maximum 
extractable BMP-4 level, the bone matrix demineralized to 14.5% calcium produced 18% 
of the maximum extractable BMP-4 level, and the 18% residual calcium bone matrix 
yielded 12% of the maximum extractable BMP-4 level. The non-demineralized bone 
matrix did not exhibit any extractability ofBMP-4 in this assay.
ANOVA analysis indicated that there were significant differences among the 
extractability ofBMP-4 from DBM with different degrees of residual calcium (P < 0.05). 
Tukey-type multiple comparison test revealed that the extensively demineralized bone
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Table 5. The effect of residual calcium on the extractability ofBMP-4 in DBM
Time Percent residual calcium Extractable BMP-4 level (pg/g DBM) % of the highest level of BMP-4
0 25 0 0
45 18 419 12
90 14.5 657 18
135 9 930 26
180 1.8 1997 56
225 0.8 2593 73
300 0.05 3571 100
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matrix (0.05% calcium content) had significantly higher extractable BMP-4 level than 
DBM with residual calcium contents of 0.8, 1.8, 9.0, 14.5, and 18.0% and yielded the 
highest BMP-4 level in the protein extracts derived from DBM.
Generally, the residual calcium contents of DBM significantly affected 
extractability ofBMP-4. Non-demineralized bone matrix did not provide for any 
extractable BMP-4, and as the residual calcium content decreased the extractability of 
BMP-4 of bone matrix increased. The 0.05% residual calcium bone matrix resulted in 
the highest level of extractable BMP-4.
1.3 The effect of particle size on extractability ofBMP-4
The effect of particle size on extractability ofBMP-4 from DBM was evaluated 
using the quantitative BMP-4 in vitro assay. Equivalent amounts (100 mg) of DBM with 
different particle size were extracted by collagenase digestion. Extractable BMP-4 levels 
were measured using BMP-4 ELISA.
The effects of particle size on extractability ofBMP-4 from DBM were compared 
and demonstrated in Figure 6. Results are representative of at least two independent 
experiments. Different particle sizes of DBM exhibited distinct effects on extractability 
ofBMP-4. The effects of particle size on extractability ofBMP-4 were assessed using 
BMP-4 ELISA. Demineralized bone particles in the 550 to 710 micron size range 
exhibited the highest levels of extractable BMP-4 when compared to similarly 
demineralized DBM of different particle size ranges. From the <250 micron particle size 
range of DBM to the 550 to 710 micron particle size range of DBM, as the particle size 
increased the extractability ofBMP-4 from DBM increased. Smaller particle sizes and
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Figure 6. BMP-4 levels in protein extracts of demineralized bone particles of variable particle size 
ranges. DBM with different particle size ranges were extracted and extractable BMP-4 levels were 
determined using BMP-4 ELISA. Data are shown as means with error bars representing standard error 
of the mean (SEM) (n=3).
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larger particle sizes resulted in lower levels of extractable BMP-4, such that DBM bone 
particles in the 355 to 550 micron and 710 to 850 micron particle size groups provided 
for equivalent levels of extractable BMP-4. As shown in Table 6, DBM in the <250 
micron bone particle size range showed extractable BMP-4 levels which approximated 
64% of the highest extractable BMP-4 levels observed, and DBM in the 250 to 355 
micron bone particle size range yielded extractable BMP-4 levels approximating 72% of 
the highest extractable BMP-4 levels observed.
ANOVA analysis revealed that there were significant differences among the 
extractable BMP-4 levels of DBM in the different bone particle size groups (P < 0.05). 
Tukey-type multiple comparison test indicated that the 550 to 710 micron bone particle 
size group had significantly greater extractable BMP-4 than DBM in all other bone 
particle size groups tested. There were no significant differences in extractable BMP-4 
levels of DBM between the <250 micron and the 250 to 355 micron, the 250 to 355 
micron and the 355 to 550 micron, and the 355 to 550 micron and the 710-850 micron 
bone particle size groups as displayed in Table 7.
Generally, particle size of DBM exhibited a significant effect on the extractability 
ofBMP-4. Under identical conditions of demineralization the 550 to 710 micron particle 
size resulted in the maximum level of extractable BMP-4. The DBM particle size 710 to 
850 micron and 355 to 550 micron illustrated equivalent levels of extractable BMP-4.
The DBM particle size range <250 micron possessed the minimum level of extractable 
BMP-4.
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Table 6. The effect of particle sizes on extractability ofBMP-4 in DBM (expressed as the 
percentage of the highest level of extractable BMP-4)






Table 7. Statistical analysis of the effect of particle size on extractability ofBMP-4 in 
DBM. Tukey-type multiple comparison, Probability level: 0.05
Subset1 1: <250 micron2 , 250-355 micron 
Subset 2: 250-355 micron, 355-550 micron 
Subset 3: 355-550 micron, 710-850 micron 
Subset 4: 550-710 micron
1 Subset is a term used in Tukey-type multiple comparison. There is a statistically significant difference 
among the particle size groups that appear in different subsets. There is no statistically significant 
difference among the particle size groups that appear in the same subset.
2 The particle size group represents the particle size group of DBM tested in the quantitative BMP-4 in 
vitro assay.
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1.4 The effect of donor age on extractability ofBMP-4
Demineralized bone matrices with residual calcium levels approximately 2% were 
provisioned by LifeNet. The DBM samples were classified into 3 age groups according 
to the donor age as follows: 0 to 25 years of age (n=T4), 26 to 44 years of age (n=15), and 
more than 45 years of age (n=T 1). As demonstrated in Figure 7, there was an age- 
dependent decline in extractable BMP-4 level as measured by BMP-4 ELISA. DMB 
from donors in the age group 0 to 25 years of age provided the maximum levels of 
extractable BMP-4, 4572 pg/g of DBM. DBM from donors in the age groups of 26 to 44, 
and more than 45 provided the extractable BMP-4 levels of 3383, and 3035 pg/g of 
DBM, respectively, which are significantly less than the extractable BMP-4 levels 
obtained from the donors in the age group 0 to 25 years of age.
1.5 Extractability ofBMP-4 as a function of male donor age
The effects of male donor age on the extractability ofBMP-4 in DBM were 
expressed as levels of extractable BMP-4 as illustrated in Figure 8. The data illustrated in 
Figure 8 indicate that extractability ofBMP-4 varies as a function of male donor age. 
DBM from the male donors in the age group 0 to 25 years of age (n=5) resulted in the 
highest levels of extractable BMP-4 (4432 pg/g of DBM). DBM from the male donors 
older than 25 showed a decline in the levels of extractable BMP-4, for example, 3780 
pg/g of DBM for the 26 to 44 year age group (n=10) and 3353 pg/g of DBM for the >45 
year age group (n=7). However, there was no statistically significant difference in the 
extractable BMP-4 among DBM samples derived from male donors.
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Figure 7. The effect of donor age on the extractability of BMP-4 in DBM. DBM from different donors 
were divided into 3 age groups as described and extracted by collagenase digestion. Extractable BMP-4 
level of DBM was measured using BMP-4 ELISA and expressed as pg of BMP-4 per g of DBM. Data are 
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Figure 8. The effect of male donor age on the extractability of BMP-4 in DBM. DBM from different 
donors was categorized into the age groups as described and extracted by collagenase digestion. 
Extractable BMP-4 level of DBM was measured using BMP-4 ELISA and expressed as pg of BMP-4 







1.6 Extractability ofBMP-4 as a function of female donor age
The effects of female donor age on the extractability ofBMP-4 were examined 
and the data are presented in Figure 9. The maximum levels of extractable BMP-4 were 
observed in the female donors in the age group 0 to 25 years of age (n=9) (4649 pg/g of 
DBM), which is the same as the corresponding male group. DBM from the female 
donors in the age groups of 26 to 44 (n=5), and >45 (n=4) provided the extractable BMP- 
4 levels of 2590, and 2479 pg/g of DBM, respectively, which are significantly lower than 
the extractable BMP-4 levels obtained from the female donors in the age group 0 to 25 
years of age. The data indicate that there is an age-dependent decrease in the levels of 
extractable BMP-4 derived from DBM of female donors.
The results of the effects of age and gender were analyzed and are illustrated in 
Table 7. DBM from the female donors in the age group 0 to 25 years of age provided the 
greatest levels of extractable BMP-4 among all of the donor age groups tested (both male 
and female) and was designated as 100% extractability. DBM from the male donors in 
the age group 0 to 25 years of age exhibited 95% of the highest extractability. The 
percentage of the highest extractability provided by DBM from other donor age and 
gender groups can be put in order from large to small as the following series: DBM from 
male 26 to 44 year age group (81%), DBM from male >45 year age group (72%), DBM 
from female 26 to 44 year age group (56%), and DBM from female >45 year age group 
(53%).
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Relationship Between Age Group of Female and BMP-4
5500 
5000 
g  4500 
g  4000 
E 3500 
3000 
g  2500 









Figure 9. The effect of female donor age on the extractability of BMP-4 in DBM. DBM from different 
donors was categorized into the age groups as described and extracted by collagenase digestion. 
Extractable BMP-4 level of DBM was measured using BMP-4 ELISA and expressed as pg of BMP-4 
per g of DBM. Data are shown as means with error bars representing standard error of the mean (SEM).
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Table 8. The effect of age and gender on the extractability of BMP-4 in DBM (expressed 
as percentage of the highest level of extractable BMP-4)
Age Group Extractable BMP-4 level (pg/g DBM) 
Male donor Female donor
% of the highest level of BMP-4 
male donor Female donor
<25 4432 4649 95 100
26-44 3780 2590 81 56
>45 3353 2479 72 53
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1.7 Correlation of extractable BMP-4 levels of DBM and osteoinductivity
The osteoinductive potential of DBM is prominently attributed to the availability 
of BMP present in DBM. Among the BMP family, BMP-4 is one of the most 
osteoinductive factors and has been investigated for clinical applications. Therefore, it is 
essential to investigate the relationship between the levels of extractable BMP-4 from 
DBM and the osteoinductivity of that DBM in the in vivo athymic mouse bioassay. Bone 
samples of 40 donors demineralized under production conditions at LifeNet were 
extracted and analyzed by BMP-4 ELISA. In addition, the osteoinductivity of DBM 
from the same donors quantitated by BMP-4 ELISA were assessed using the in vivo 
athynic mouse bioassay. As demonstrated in Figure 10, the amounts of the extractable 
BMP-4 in the protein extracts of DBM were variable among DBM samples. The 
extractable BMP-4 levels ranged between 1.82 and 7.94 ng/g of DBM (mean = 3.7 ± 0.21 
ng BMP-4/ g of DBM). Figure 11 illustrated that DBM samples possessing high 
osteoinductivity in the nude mouse bioassay contained greater BMP-4 levels in the 
protein extracts from these DBM than those DBM samples exhibiting low levels of 
osteoinductivity. There was a good positive correlation between the quantitative BMP-4 
in vitro assay and osteoinduction (percentage of new bone formation) determined by the 
implantation of DBM in the in vivo nude mouse bioassay with a correlation coefficient of 
0.74 (P < 0.001).
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Figure 11. Correlation between extractable BMP-4 levels of DBM determined by ELISA and 
percentage of new bone formation (in vivo) determined by histomorphometric analysis. A total of 40 
DBM samples from 40 different donors were divided into two portions, one portion was used in the 
quantitative BMP-4 in vitro assay with the second portion used in the in vivo athymic mouse bioassay. 
Correlation was analyzed by the linear regression analysis (SPSS 10.00). Regression coefficient (R) 
was 0.74 (P< 0.001).
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2. GENE EXPRESSION ANALYSIS OF OSTEOBLAST DIFFERENTIATION
2.1 Initiation and characterization of HPO/LN-SHOl cell line
A human periosteal cell line was acquired using the outgrowth technique from the 
periosteum (Figure 12 and 13) as described in the Materials and Methods. This cell line 
was established by propagation of the primary cultured periosteal cell line to approximate 
passage 4 and was designated HPO/LN-SHOl, and phenotypic characteristics were 
maintained over the course of this study by cryopreservation. All cells used in this study 
were from this cell line. In bone repair it has been suggested that osteoblast progenitor 
cells migrate from the periosteum and differentiate into osteoblast cells that in turn result 
in the new bone formation (Ham and Harris, 1956).
The morphologic pattern of HPO/LN-SHOl cells in cell culture is demonstrated in 
Figure 14. Cultured in the minimum essential media supplemented with 10% FBS, the 
periosteal cells exhibited spindle and stellate shapes with fine homogenous cytoplasm, 
typically associated with fibroblast-like cells. The most distinguishing characteristic of 
the cell line is the long processes. When confluent, as shown in Figure 15, HPO/LN- 
SHOl cells were aligned in orderly manner and displayed a regular confluent pattern 
where some areas have high cell density and some areas have lower cell densities.
2.2 Ability of DBM-CM to induce alkaline phosphatase activity in HPO cells
Previous studies in our laboratory demonstrated that DBM has osteoinductive 
potential in in vitro assays. However, the biochemical mechanism(s) behind this 
osteoinductive process in the in vitro cell culture system remains unknown. It has been 
postulated that the DBM either releases the inducing stimulus or the stimulus may be 
mediated through a direct DMB-osteoprogenitor cell interaction.
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Figure 15. Confluent HPO/LN-SHOl cells in monolayer culture ( x 10). Cells were cultured in alpha- 
MEM supplemented with 10% FBS and penicillin (100 units/ml)/streptomycin (50 pg/ml).
<!o
71
To determine whether the osteoinductive proteins or other factors represent a soluble 
component of DBM released and distributed into the media in vitro, conditioned media 
were prepared from DBM. DBM was suspended in serum-deprived DMEM for 4 weeks 
in the cold room (0-4°C). The conditioned medium was centrifuged to separate and 
remove DMB and then concentrated using a 10 kDa pore size, centrifugal device 
(Millipore). Next this concentrate was measured for protein concentration by using a 
BCA (Bicinchoninic acid) protein assay, then aliquotted and stored at -80°C.
To assess dose dependence, various concentrations of DBM-conditioned media 
(DBM-CM), 1, 10, 50, 100 pg/ml were added to separate confluent cell cultures of HPO 
cells. HPO cells without DBM-CM treatment served as a control. The alkaline 
phosphatase activities were assayed on day 5 after the treatment. The results are 
representative of at least two independent experiments and are displayed in Figure 16.
The addition of increasing concentrations of DBM-CM enhanced alkaline phosphatase 
activities ofHPO cells in a dose-dependent manner. The alkaline phosphatase activity 
was maximal at the highest concentration tested (100 pg/ml). These results indicate that 
there are soluble osteoinductive factors that can diffuse from the DBM and become 
distributed into the media.
2.3 Morphologic and histochemical studies of the effects of DBM-CM on HPO cells
Morphologic and histochemical studies were also conducted for DBM-CM. DBM- 
CM (100 pg/ml) was added to the confluent cell culture ofHPO cells. HPO cells without 
DBM-CM treatment were used as a control. After 5 days of incubation, Cell morphology














Effect of DBM-CM on ALP activity in HPO cells
DBM-CM concentration (ugfail)
Figure 16. Alkaline phosphatase activity assay of DBM-CM dose response study. DBM-CM (0,1,10, 
50, 100 pg/ml were added into confluent flasks of HPO/LN-SHOl cells. Alkaline phosphatase activity 
were measured after 5 days of DBM-CM treatment. Data are shown as means with error bars 
representing standard error of the mean (SEM) (n=3).
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was observed and alkaline phosphatase staining assay was performed. The control cells 
(without DBM-CM treatment) possess a spindle shape, and there was very little 
extracellular matrix as demonstrated in Figure 17. In contrast, the DBM-CM treated cells 
(Figure 18) appeared shortened and flattened, and they were surrounded by extracellular 
matrix. Furthermore, in the control slides, cells were stained blue (Figure 19), suggesting 
low levels of alkaline phosphatase activity. On the other hand, in the DBM-CM treated 
slides, a strong red and purple color appeared in all the areas (Figure 20) indicating very 
high alkaline phosphatase activities. These histochemical studies confirmed that DBM- 
CM has a strong stimulatory effect on the alkaline phosphatase activities ofHPO cells, a 
very early marker of cell differentiation into the osteogenic lineage.
2.4 Gene expression profiling of HPO/LN-SHO1 cells during osteogenic differentiation 
cDNA gene expression arrays are rapidly becoming the method of choice to 
examine gene expression profiles in various specialized systems and to discover new 
bone-related genes which may play essential roles in osteoblast development. To attain a 
profile of gene expression during differentiation, total RNA was harvested from HPO 
cells in the absence or presence of DBM-CM at day 7 and used as template for synthesis 
of biotin labeled cDNA probes and hybridized to human osteogenesis gene arrays 
containing 96 cDNA fragments. The recorded raw array images were scanned and 
converted into a digital image file. The scan results were saved under TIFF format and 
subsequently analyzed using a program called ScanAlyze (written by Michael Eisen, 
Stanford University). Images were gridded to locate the spot corresponding to each gene 
as illustrated in Figure 21. Following gridding, information on each spot, including














Figure 17. Morphology study of human periosteal cells without DBM-CM addition ( x 10). HPO/LN- 
SHOl cells were incubated in DMEM assay media alone for five days. Spindle-like cells with little 















Figure 18. Morphology study of the effects of DBM-CM on human periosteal cells ( x 10). HPO/LN- 
SHOl cells were incubated with DBM-CM (100 pg/ml) and DMEM assay media for five days. Cells 
retracted from some areas which are surrounded with extracellular matrix.
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intensities, background intensities and ratios, was extracted using ScanAlyze and 
presented as a Microsoft Excel file. Ratios were ultimately used to determine 
differentiation of gene expression. Genes with ratio number above 2 or under 0.5, i.e., 2 
fold induction or repression, were selected and subjected to further analysis. Table 9 lists 
the names, accession numbers, and description of genes present in the cDNA array. The 
array in this study contains pUC18 as a negative control and also contains GAPDH, 
cyclophilin A, RPL13A, and P-actin as positive controls, which were averaged to create a 
normalization value for each array.
To ensure reproducibility of cDNA array results, the assay was repeated twice 
using independent RNA samples. Figure 22 represents typical hybridization result in 
which the cDNA probe derived from non-treated cells and the cDNA probe from DBM- 
CM-treated cells. Using a cutoff value of 2 fold, which is conventionally used by similar 
studies, 3 genes were found to be up-regulated more than 2-fold. Only 1 gene appeared 
to be down-regulated more than 2-fold during the differentiation process. A list of 
identified genes is shown in Figure 23. Among the up-regulated genes during osteogenic 
differentiation, biglycan coding for extracellular matrix protein is a prominent 
osteoblastic marker which has previously been associated with the development and 
function of osteoblasts and has been shown to play an important role in the bone 
formation (Xu etal., 1998). Interestingly, TGF-pl involved in the enhancement of the 
formation of extracellular matrix and inhibition of matrix degradation was also up- 
regulated, including its receptor, TGF-PRl. In contrast, expression of the gene encoding














1 2 3 4 5 6 7 8
ALPL ANXA5 ARSE BGLAP BGN BMP1 BMP2 BMP3
9 10 11 12 13 14 15 16
BMP4 BMP5 BMP6 BMP7 BMP8 BMPR1A CASR CD36
17 18 19 20 21 22 23 24
CD36L1 CD36L2 COL10A1 COL11A1 COL12A1 COL14A1 COL15A1 COL16A1
25 26 27 28 29 X 31 32
COL17A1 COL18A1 COL19A1 COL1A1 COL2A1 COL3A1 COL4A3 COL4A4
33 34 35 36 37 38 39 40
COL4A5 COL5A1 COL7A1 COL9A2 CSF2 CSF3 CTSK DCN
41 42 43 44 45 46 47 48
EGF EGFR FGF1 FGF2 FGF3 FGFR1 FGFR2 FGFR3
49 50 51 52 53 54 55 56
FLT1 FN1 GDF10 ICAM1 IGF1 IGF1R IGF2 ITGA1
57 58 59 60 61 62 63 64
ITGA2 (TGA3 ITGAM ITGAV ITGB1 MADH1 MADH2 MADH3
65 66 67 68 69 70 71 72
MADH4 MADH5 MADH6 MADH7 MADH9 MMP10 MMP13 m /P2
73 74 75 76 77 78 79 80
fvMPB WSX1 MSX2 NFKB1 PDGFA RUNX2 SERPINH1
81 82 83 84 85 86 87 88
SERPINH2 SOX9 SPARC SPP1 TGFB1 TGFB2 TGFB3 TGFBR1
89 90 91 92 93 94 95 96
TGFBR2 TNF TWIST VCAM1 VDR VEGF VEGFB VEBFC
97 98 99 100 101 102 103 104
PUC18 PUC18 PUC18 Blank Blank Blank GAPD GAPD
105 106 107 108 109 110 111 112
PPIA PPIA PPIA PPIA RPL13A RPU13A ACTB ACTB
Figure 21. Grid located the spot corresponding to each gene in cDNA array.
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Table 9. List of names, accession numbers, and description of genes present in human 
osteogenesis cDNA array
Position UniGene Genebank Symbol Description Gene name
1 Hs.250769 NM 000478 ALPL Alkaline phosphatase, liver/bone/kidney ALP
2 Hs.79274 NM 001154 ANXA5 Annexin V annexin v
3 Hs.74131 NM 000047 ARSE Arylsulfatase E ARSE
4 Hs.2558 X52698 BGLAP Bone gamma-carboxyglutamate (gla) protein Osteocalcin
5 Hs.821 J04599 BGN Biglycan Biglycan
6 Hs.1274 NM 006128 BMP1 Bone morphogenetic protein 1 BMP1
7 Hs.73853 NM 001200 BMP2 Bone morphogenetic protein 2 BMP2
8 Hs. 121507 NM 001201 BMP3 Bone morphogenetic protein 3 BMPS
g Hs.68879 NM 001202 BMP4 Bone morphogenetic protein 4 BMP4
10 Hs.1104 NM 021073 BMP5 Bone morphogenetic protein 5 BMP5
11 Hs.285671 NM 001718 BMP6 Bone morphogenetic protein 6 BMP6
12 Hs.170195 NM 001719 BMP7 Bone morphogenetic protein 7 BMP7
13 Hs.99948 NM 001720 BMP8 Bone morphogenetic protein 8 BMP8
14 Hs.2534 NM 004329 BMPR1A Bone morphogenetic protein receptor, type IA ALK-3
15 Hs.272429 U20760 CASR Calcium-sensing receptor CASR
16 Hs.75613 NM 000072 CD36 Homo sapiens CD36 antigen CD36
17 Hs.180616 NM 005505 CD36L1 CD36 antigen-like 1 CD36L1
18 Hs.85963 AK025446 CD36L2 CD36 antigen-like 2 CD36L2
19 Hs.179729 NM 000493 COL10A1 Type X collagen a1 COL10A1
20 Hs.82772 NM 080629 COL11A1 Type XI collagen a1 COL11A1
21 Hs.101302 NM 004370 COL12A1 Type XII collagen a1 COL12A1
22 Hs.36131 BC014640 COL14A1 Type XIV collagen a1 COL14A1
23 Hs.83164 NM 001855 COL15A1 Type XV collagen a1 COL15A1
24 Hs.26208 NM 001856 COL16A1 Type XVI collagen a1 COL16A1
25 Hs.117938 NM 000494 COL17A1 Type XVII collagen a1 COL17A1
26 Hs.78409 AF18081 COL18A1 Collagen, type XVIII, alpha 1 Endostatin
27 Hs.89457 NM 001858 COL19A1 Type XIX collagen a1 COL19A1
28 Hs.172928 NM 000088 COL1A1 Collagen type I (a) COL1A1
29 Hs.81343 NM 001844 COL2A1 Type II collagen a1 COL2A1
30 Hs.119571 NM 000090 COL3A1 Collagen, type III, alpha 1 COL3A1
31 Hs.530 NM 000091 COL4A3 Type IV collagen a3 COL4A3
32 Hs.180828 NM 000092 COL4A4 Type IV collagen a4 COL4A4
33 Hs.169825 NM 033380 COL4A5 Type IV collagen a5 COL4A5
34 Hs.146428 NM 000093 COL5A1 Type V collagen a1 COL5A1
35 Hs.1640 NM 000094 COL7A1 Collagen, type VII, alphal COL7A1
36 Hs.37165 NM 001852 COL9A2 Type IX collagen a2 COL9A2
37 Hs.1349 M11734 CSF2 Colony stimulating factor 2 GM-CSF
38 Hs.2233 X03438 CSF3 Colony stimulating factor 3 G-CSF
39 Hs.83942 NM 000396 CTSK Cathepsin K CTSK
40 Hs.76152 NM 001920 DCN Decorin Decorin
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Table 9. (continue)
Position UniGene Genebank Symbol Description Gene name
41 Hs.2230 X04571 EGF Epidermal growth factor (beta-urogastrone) EGF
42 Hs.77432 X00588 EGFR Epidermal growth factor receptor EGFR
43 Hs.75297 X51943 FGF1 Fibroblast growth factor 1 (acidic) FGF1
44 Hs.284244 NM 002006 FGE2 Fibroblast growth factor 2 (basic) FGE2
45 Hs.37092 X14445 FGF3 Fibroblast growth factor 3 FGF3 (int-2)
46 Hs.748 M34185 FGFR1 Fibroblast growth factor receptor 1 FGFR1
47 Hs.278581 M55614 FGFR1 Fibroblast growth factor receptor 2 FGFR2
48 Hs.1420 M64347 FGFR3 Fibroblast growth factor receptor 3 FGFR3
49 Hs.138671 NM 002019 FLT1 Vascular endothelial growth factor receptor FLT1
50 Hs.287820 X02761 FN1 Fibronectin 1 Fibronectin-1
51 Hs.2171 NM 004962 GDF10 Growth differentiation factor 10 BMP3B
52 Hs.168383 NM 000201 ICAM1 Intercellular adhesion molecule 1 (CD54) ICAM-1
53 Hs.85112 M27544 IGF1 Insulin-like growth factor 1 IGF-1
54 Hs.173231 X04434 IGF1R insulin-like growth factor 1 receptor IGF-1R
55 Hs.349109 M29645 IGF2 Insulin-like growth factor 2 IGF-II
56 Hs.116774 X68742 ITGA1 Integrin, alpha 1 Integrin a1
57 Hs.271986 X17033 ITGA2 Integrin, alpha 2 Integrin a2
58 Hs.265829 M59911 ITGA3 Integrin, alpha 3 Integrin a3
59 Hs.172631 J04145 ITGAM Integrin, alpha M Integrin aM
60 Hs.295726 NM 002210 ITGAV Integrin, alpha V Integrin aV
61 Hs.287797 NM 002211 ITGB1 Integrin, beta 1 Integrin b1
62 Hs.79067 U59912 MADH1 MAD homolog 1 SMAD1
63 Hs.82483 NM 005901 MADH2 MAD homolog 2 SMAD2
64 Hs.211578 NM 005902 MADH3 MAD homolog 3 SMAD3
65 Hs.75862 U44378 MADH4 MAD homolog 4 DPC4/SMAD4
66 Hs.37501 NM 005903 MADH5 MAD homolog 5 SMAD5
67 Hs,153863 NM 005585 MADH6 MAD homolog 6 SMAD6
68 Hs.100602 NM 005904 MADH7 MAD homolog 7 SMAD7
69 Hs.123119 NM 005905 MADH9 MAD homolog 9 SMAD9
70 Hs.2258 NM 002425 MMP10 Matrix metailoproteinase 10 MMP10
71 Hs.2936 X75308 MMP13 Matrix metailoproteinase 13 Collagenase-3
72 Hs.111301 J03210 MMP2 Matrix metailoproteinase 2 Gelatinase A
73 Hs.73862 NM 002424 MMP8 Matrix metailoproteinase 8 MMP8
74 Hs.151738 J05070 MMP9 Matrix metailoproteinase 9 Gelatinase B
75 Hs.1494 NM 002448 MSX1 Homeobox 7, MSH homeobox homolog 1 Hox7
76 Hs.89404 NM 002449 MSX2 MSH homeobox homolog 2 MSX2
77 Hs.83428 M58603 NFKB1 Nuclear factor of kappa enhancer in B cells 1 NFkB
78 Hs.37040 X06374 PDGFA Platelet-derived growth factor alpha PDGFa
79 Hs.121895 L40992 RUNX2 Runt-related transcription factor 2 CBFA1
80 Hs.241579 NM 004353 SERPINH1 Serine proteinase inhibitor, clade H, member 1 CBP1
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Table 9. (continue)
Position UniGene Genebank Symbol Description Gene name
81 Hs.9930 NM 001235 SERPINH2 Serine proteinase inhibitor, clade H, member 2 CBP2
82 Hs.2316 NM 000346 SOX9 SRY-box9 SOX9
83 Hs.111779 XM 003989 SPARC Secreted protein, acidic, cysteine-rich Osteonectin
84 Hs.313 M83248 SPP1 Secreted phosphoprotein 1 OPN
85 Hs.1103 X02812 TGFB1 Transform ng growth factor, beta 1 TGFbl
86 Hs.169300 M19154 TGFB2 Transform ng growth factor, beta 2 TGFb2
87 Hs.2025 NM 003239 TGFB3 Transform ng growth factor, beta 3 TGFb3
88 Hs.220 L11695 TGFBR1 Transform ng growth factor, beta receptor I TGFBR1
89 Hs.82028 D50683 TGFBR2 Transform ng growth factor, beta receptor II TGFBR2
90 Hs.241570 X01394 TNF Tumor necrosis factor (TNF superfamily) TNFa
91 Hs.66744 NM 000474 TWIST Homolog of Drosophilia TWIST TWIST
92 Hs.109225 M30257 VCAM1 Vascular cell adhesion molecule 1 VCAM-1
93 Hs.2062 NM 000376 VDR Vitamin D hormone receptor VDR
94 Hs.73793 NM 003376 VEGF Vascular endothel al growth factor VEGF
95 Hs.78781 U48801 VEGFB Vascular endothel al growth factor B VEGF-B
96 Hs.79141 X94216 VEGFC Vascular endothel al growth factor C VEGF-C
97 N/A L08752 PUC18 PUC18 Plasmid DNA pUC18
98 N/A L08752 PUC18 PUC18 Plasmid DNA pUC18
99 N/A L08752 PUC18 PUC18 Plasmid DNA pUC18
100 Blank Blank Blank Blank O
101 Blank Blank Blank Blank O
102 Blank Blank Blank Blank O
103 Hs.169476 M33197 GAPD Glyceraldehyde-3-phosphate dehydrogenase GAPDH
104 Hs.169476 M33197 GAPD Glyceraldehyde-3-phosphate dehydrogenase GAPDH
105 Hs.342389 NM 021130 PPIA Peptidylprolyl isomerase A cyclophilin A
106 Hs.342389 NM 021130 PPIA Peptidylproiyl isomerase A cyclophilin A
107 Hs.342389 NM 021130 PPIA Peptidylprolyl isomerase A cyclophilin A
108 Hs.342389 NM 021130 PPIA Peptidylprolyl isomerase A cyclophilin A
109 Hs.119122 NM 012423 RPL13A Ribosomal protein L13a RPL13A
110 Hs.119122 NM 012423 RPL13A Ribosomal protein L13a RPL13A
111 Hs.288061 X0Q351 ACTB Beta Actin b-actin
112 Hs.288061 XQ0351 ACTB Beta Actin b-actin















Figure 22. Images of osteogenesis cDNA array used for gene expression analysis. HPO/LN-SHOl 
cells were harvested for RNA isolation at day 7 and processes as described in “Materials and 
Methods”. Total cell RNA (5ug) was used for analysis. C, control (cells without DBM-CM treatment); 















Control Treatment Gene Name Ratio Treatment/Control
Biglycan >2
I Collagen 14A1 <0.5
r TGF-31 >2
TGF-(3R1 >2
Figure 23. Comparison of gene expression of HPO/LN-SHOl cells without (control) and with 
(treatment) DBM-CM addition using cDNA array analysis. The expression array signals for biglycans, 
collagenl4Al, TGF-pl, and TGF-|3R1 are shown.
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for collagenl 4Al was down-regulated. This decrease might have implications during the 
process o f bone development because collagenl 4 Al occurs in virtually every collagen I- 
containing tissue (periosteum, tendon, skeletal muscle, cardiac muscle, and nerve) 
(Walchli etal., 1994).
2.5 Verification of expression of selected genes using RT-PCR analysis
To verify the cDNA array results, RT-PCR analysis was performed using Poly 
(A)+ RNA prepared from the same conditions as used in cDNA array studies. Among up- 
regulated genes, biglycan found to be highly up-regulated gene was selected. Gene 
encoding for collagenl4Al was chosen for down-regulated gene. A housekeeping 
GAPDH gene, whose expression was unchanged during osteogenic differentiation, was 
chosen to serve as an internal control. RT-PCR analysis of parallel samples was 
consistent with the cDNA array data in that there was an increase in the level of biglycan 
expression after day 7 of DBM-CM treatment (Figure 24). Also, in agreement with the 
cDNA array analysis, expression of the gene encoding for collagenl4Al decreased after 
day 7 of DBM-CM addition (Figure 26). Figure 25 and 27 shows the normalized gene 
expression levels of RT-PCR bands for biglycan and collagenl 4 Al respectively. The 
RT-PCR results demonstrated identical expression pattern for selected genes as revealed 
by cDNA array analysis.
To examine the temporal expression of biglycan and collagenl 4 Al in HPO cells 
non-treated or treated with DBM-CM, poly (A)+ RNA was purified for RT-PCR analysis 
at days 0, 4, 7, 10, and 14 in the absence or presence of DBM-CM. Figure 28 and 29 
illustrate the time course of biglycan mRNA expression relative to that of GAPDH 
mRNA in HPO cells without DBM-CM treatment. Figure 30 and 31 show time line of
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Figure 24. RT-PCR showing the up-regulation of biglycan in HPO/LN-SHOl cell line. GAPDH was 
used as an internal control. C, control (cells without DBM-CM treatment); T, treatment (cells with 
DBM-CM treatment); +, positive control in RT-PCR; -, negative control in RT-PCR; No RT, no 
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Figure 25. Densitography of the gel electrophoresis from Figure 24. Biglycan mRNA expression of 
HPO/LN-SHOl cells in the absence (control) or presence of DBM-CM on day 7 was normalized with 
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Figure 26. RT-PCR showing the down-regulation of collagenl4Al in HPO/LN-SH01 cell line. 
GAPDH was served as an internal control. C, control (cells without DBM-CM treatment); T, treatment 
(cells with DBM-CM treatment); +, positive control in RT-PCR; -, negative control in RT-PCR;
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Figure 27. Densitography of the gel electrophoresis from Figure 26. Collagen 14A1 mRNA expression 
of HPO/LN-SHOl cells in the absence (control) or presence of DBM-CM on day 7 was normalized 
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Figure 29. Densitography of the gel electrophoresis from Figure 28. Expression profile of biglycan 
from HPO/LN-SH01 cells without DBM-CM addition (control) was shown.
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biglycan mRNA expression relative to that of GAPDH mRNA in HPO cells after 
addition of DBM-CM. On day 10 after DBM-CM treatment, biglycan mRNA expression 
reached a peak and the level increased more than 3-fold compared with that of the culture 
without treatment (Figure 32). It is intriguing to note that biglycan mRNA expression 
level in the DBM-CM treated cells was approximately 2-fold higher than that of non­
treated cells in every time point. In down-regulated gene, time course of collagenl4Al 
expression relative to that of GAPDH mRNA was demonstrated in Figure 33 and 34 for 
the non-treated HPO cells and in Figure 35 and 36 for the DBM-CM-treated HPO cells. 
The results revealed that gene expression of collagenl4Al in the DBM-CM treated cells 
decreased over time when compared with that in the untreated cells. The repression level 
of collagen!4Al was greater than 2 fold on days 4, 7, and 14.
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Figure 31. Densitography of the gel electrophoresis from Figure 30. Expression profile of biglycan 
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Figure 34, Densitography of the gel electrophoresis from Figure 33, Expression profile of 
collagen!4Al from HPO/LN-SH01 cells without DBM-CM addition was shown.
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Figure 36. Densitography of the gel electrophoresis from Figure 35. Expression profile of 
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Bone morphogenetic proteins are originally identified as protein regulators of 
cartilage and bone formation. BMPs have been implicated in embryogenesis and 
morphogenesis of various tissues and organs. BMPs can regulate growth, differentiation, 
chemotaxis and apoptosis in a variety of cell types, including mesenchymal, epithelial, 
hematopoietic and neuronal cells. BMP-4 plays an essential role in the onset of bone 
formation, dorsal/ventral patterning (Graff, 1997) and has also been implicated in the 
commitment of embryonic mesodermal cells to a hematopoietic fate in a number of 
system (Leong et al., 1996; Reddi, 1998; Wozney, 1992). BMP-4 is also involved in 
prenatal and postnatal endochondral ossification. Deregulation of BMP-4 expression is 
associated with fibrodysplasia ossificans progressiva (Xu et al., 1998; Shore et al., 1998). 
In addition to this heterotopic bone formation, it also is suggested that BMP-4 plays a 
role in bone fracture repair. It has become evident that early in the process of fracture 
healing, the concentration of BMP-4 increases (Bostrom et al., 1995). Recombinant 
human BMP-4 (rhBMP-4) effectively enhances new bone formation and accelerates 
fusion of the rabbit posterolateral posterior spinal fusion model in a dose-dependent 
fusion (Cheng et al., 2002; Guo et al., 2002). Additionally, the recent studies showed 
that rhBMP-2-containing demineralized bone allograft resulted in a dose-dependent 
increase in new bone formation (Schwartx et al., 1998; Niederwanger et al., 1996). It is 
generally accepted that the BMPs present in demineralized bone materials reflect to their 
ability to induce new bone formation.
The current study investigated whether BMP-4 could be identified and quantitated 
in the protein extracts of DBM. The data demonstrated that BMP-4 was present and
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could be detected in the protein extracts of DBM by using Western blotting and ELISA.
A recent study has shown that BMP-4 was observed in the extracts of demineralized 
freez-dried bone allograft (DFDBA) by slot blot analysis (Shigeyama et a l, 1995). It is 
plausible that BMPs other than BMP-4 are also present in the extracts of DFDBA since 
BMP-2 and BMP-7 have also been demonstrated to be present in the extracts of DFDBA, 
but we did not specifically investigate for these. Both BMP-2 and BMP-7 are also the 
most osteoinductive proteins that are able to induce heterotopic bone formation (Wozney 
et al, 1998). Future investigations with BMP-2 and BMP-7 will need to determine the 
presence and quantities of BMP-2 and BMP-7 in the protein extracts of DBM as they are 
relevant to the potential for induction of new bone formation.
In apparent contrast to the results of this study, BMP-2 and BMP-4 were reported 
to be undetectable in the extracts of DFDBA by immunoprecipitation coupled with 
Western blot analysis (Li et a l, 2000). This discrepancy could be attributable to different 
extraction methods, inability of the antibody used in that study to recognize its target 
epitope, and/or sensitiviy of assays utilized. The results of the present study suggest that 
BMPs are covered by the minerals and tightly associated with collagen fibers. 
Furthermore, the amount of BMPs is small. Therefore, BMPs would not be detectable 
without extensive demineralization and appropriate extraction. This may explain the 
failure of others to detect BMP-4. However, this finding in the present study is in 
accordance with that of Wozney (Wozney, 1992), who reported that BMPs are found in 
microgram quantities per kilogram of cortical bone. We demonstrated that the level of 
extractable BMP-4 in DBM was in the range of nanogram per gram of DBM.
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The data of this study revealed that non-demineralized bone matrix did not yield 
extractable BMP-4 whereas slightly demineralized bone matrix provided a degree of 
extractability of BMP-4, as the mineral content decreased the extractability of BMP-4 
increased. Expectedly, the observation that the non-demineralized bone matrix showed 
no detectable BMP-4 level supports the widely known concept that BMPs are trapped by 
the minerals, and demineralization will expose BMPs relatively proportional to the 
degree of demineralization. Obviously, the more bone matrix is demineralized, the more 
minerals are removed, and the more BMPs become liberated and extractable from the 
DBM. Additionally, in the particle size study, we also illustrated that bone particle size 
had a striking effect on the extractability ofBMP-4 from DBM. Bone particles between 
550 micron and 710 micron provided for the highest levels of extractable BMP-4 and 
appear to represent the optimal size range in that bone particles of larger or smaller sizes 
provided lower extractable BMP-4 levels. Interestingly, this finding is in agreement with 
the previous observation in our laboratory in that DBM in the 550 to 710 micron bone 
particle size range provided for maximum osteoinductive potential in in vitro and in vivo 
bioassays (Zhang et al., 1997).
For the present size study, different particle sizes of DBM were demineralized for 
equivalent periods of time to mimic the actual process of demineralizing bone in the 250 
micron to 850 micron particle size range. The previous study reported that different 
particle-sized DBM contained different levels of residual calcium where smaller particle­
sized DBM was more readily demineralized than larger particle-sized DBM (Zhang et al., 
1997). The current study demonstrated that bone particle size had a dramatic effect on 
the extractability ofBMP-4 in DBM. From the 550 to 710 micron particle size range of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
104
DBM to the <250 micron particle size range of DBM, as the particle size decreased the 
extractability ofBMP-4 from DBM declined. DBM particles less than 250 micron 
provided for minimum level of extractable BMP-4 among all size groups tested. This 
reduction may be attributable to degradation ofBMP-4 during the process of 
demineralization.
Additional data presented in this study revealed that there were donor age and 
gender-related effects on the extractability ofBMP-4 from DBM. DBM derived from 
female donors appears to contain maximally and significantly more extractable BMP-4 
when derived from donors in the age group 0 to 25 years of age than from donors in all 
other age groups tested, whereas there was no statistically significant difference in the 
extractable BMP-4 among DBM samples derived from male donors. When compared 
within each of age group, DBM from male donors in the age group 26 to 44 years of age 
and 45 years of age and older possessed more extractable BMP-4 than those from female 
donors in the same age group. However, in general, there was no statistically significant 
different in the extractable BMP-4 levels of DBM between male and female donors.
Collectively, the levels of extractable BMP-4 and the osteoinductive potential of 
DBM derived from 40 donors were investigated. The data designated a direct correlation 
between the extractable BMP-4 levels in DBM using the quantitative in vitro assay and 
the osteoinductivity of DBM from the in vivo bioassay. A linear regressional analysis 
between these 2 assessment methods exhibited a correlation coefficient (R) of 0.74 
(P < 0.001). Therefore, the quantitative BMP-4 in vitro assay could be an alternative 
means of assessing the capability of DBM to induce new bone formation. Additional 
data suggest that availability (i.e., extractability) ofBMP-4 depends upon the
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demineralization process. Hence, it is essential to the production of a reproducibly 
osteoinductive DBM product that the demineralization process be controlled and 
reproducible irrespective of the nature of the bone materials being demineralized.
The principal benefit of the quantitative BMP-4 in vitro assay for quantitating the 
osteoinductivity of demineralized bone products is time saving; results are available 
within 2 days. In contrast, the in vitro cell culture based and in vivo animal based 
bioassays required a minimum of 1 week and 4 weeks respectively to obtain information 
which may be used as a quality assessment criteria for release of produced DBM. 
Moreover, these 2 bioassays are labor consuming and involve a considerable amount of 
work, including complicated biological systems. In addition, surgical problems with 
implanted animals can be eliminated. There is no need to concern about immunological 
and inflammatory responses of tested animals to demineralized bone products. The 
quantitative BMP-4 in vitro assay described in the current study is sensitive, 
reproducible, inexpensive, and requires less than 2 days to perform.
In this study, gene expression profiling of osteogenic differentiation in human 
periosteal (HPO/LN-SHOl) cells was also examined. Osteogenic differentiation is a 
complex process and involves distinct genotypic changes that are accompanied by 
specific phenotypic alterations. Recent advances in cDNA gene expression array 
technology allow for simultaneous monitoring of a number of known and unknown genes 
in parallel. cDNA expression arrays are rapidly becoming the method of choice to 
investigate gene expression profiles in various specialized system. In the current study 
human osteogenesis gene arrays were utilized to differentially display bone-related genes 
that may play crucial roles in osteoblast development. This study investigated the
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expression of over 96 genes involved in the regulation of osteogenic differentiation. The 
observation from this study revealed that expression of biglycan was up-regulated 
whereas the expression of collagenl4Al was down-regulated in the DBM-CM treated 
cultures compare with the non-treated cultures.
Although bone is a highly specialized tissue, osteoblasts are very similar to 
fibroblasts in terms of gene expression (Ducy et al., 2000). A characteristic feature of 
osteoblasts is the secretion and processing of extracellular matrix. The strongest 
modulations were observed in the cDNA array experiments for extracellular matrix 
genes, with particularly striking up-regulation of small leucine-rich proteoglycan, 
biglycan. Proteoglycans play a role in matrix assembly and can promote in vitro matrix 
mineralization (Boskey et al., 1997). The result from the time course study of biglycan is 
in agreement with the model of osteoblast differentiation in which osteoblast 
differentiation is followed by matrix deposition and matrix maturation. This cDNA array 
study thus may extend current knowledge about the mechanism whereby osteoblasts 
deposit bone matrix.
In addition, other genes, such as alkaline phosphatase (ALP), Runx2, insulin-like 
growth factor-1 (IGF-1), and vascular endothelial growth factor (VEGF) were slightly 
up-regulated. Their induction level on cDNA array was less than 2-fold and therefore not 
included in RT-PCR analysis. Furthermore, it is essential to realize that unknown 
relevant osteoblast-specific genes might not be present on the cDNA arrays used in this 
study.
The data derived from this type of approach are broadly descriptive. However, 
the analysis presented in this study offers a screening method and a dynamic picture of
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gene expression during osteogenic differentiation. Other reports have shown in which 
gene expression during osteoblast differentiation has been investigated on a large scale by 
using gene expression array technology (Beck et al., 2001; Locklin et al., 2001). It is 
important to note that accurate comparison of these studies is difficult for several reasons: 
(1) the cDNA used in this study differs from the arrays used in other studies, therefore 
different genes are screened; (2) studies are performed in different cell lines; (3) different 
agents or inducers of osteoblast differentiation such as P-glycerophosphate, ascorbic acid, 
BMP, and conditioned media are used; and (4) expression analysis is performed at 
different time points. The ability to compare data collected on hundreds of genes under 
one set of conditions with data from other system results in overall understanding of the 
molecular basis of osteogenesis. These data are valuable not just for a better 
understanding of osteogenesis but also for the comparison with other tissue types.
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SUMMARY
In summary, the present study established and validated the quantitative in vitro 
assay for the assessment of osteoinductive potential of human demineralized bone matrix 
In addition, this study investigated the relationships between extractability ofBMP-4 and 
the residual calcium content in the DBM, the relationship between the extractability of 
BMP-4 and bone particle size, and the relationship between the extractability ofBMP-4 
and donor age and gender. The study validated the quantitative in vitro method used for 
the assessment of the osteoinductivity of DBM. Furthermore, gene expression profiling 
of osteogenic differentiation in human periosteal cells was investigated. The results 
provided insight to the biological process of osteogenic differentiation in human 
periosteal cells.
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